METHODS FOR QUANTIFICATION OF ADIPONECTIN BY MASS SPECTROMETRY
The mass spectrometry-based method for adiponectin quantification addresses the need for accurate adiponectin measurement, achieving a low detection limit and enabling effective diagnosis and prognosis of metabolic disorders and diabetes.
Patent Information
- Application Number
- BR112025020940
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-31
- Filing Date
- 2024-03-29
- Publication Date
- 2026-11-10
AI Technical Summary
There is a need for a reliable and accurate method to measure adiponectin levels, as individuals with low adiponectin levels have a higher risk of metabolic syndrome and type 2 diabetes, and high adiponectin levels provide protection against these conditions.
The method involves determining adiponectin levels in a sample using mass spectrometry by subjecting adiponectin to an ionization source, generating detectable ions, and quantifying them to determine adiponectin amounts, which can include techniques like electrovaporization ionization, atmospheric pressure chemical ionization, and high-resolution/high-precision mass spectrometry, with the addition of internal standards and sample purification steps.
This method achieves a detection limit as low as 0.75 pg/mL, allowing for accurate measurement of adiponectin levels and aiding in the diagnosis and prognosis of metabolic disorders and diabetes, with high precision and sensitivity.
Abstract
Description
1 / 64 METHODS FOR QUANTIFICATION OF ADIPONECTIN BY MASS SPECTROMETRY CROSS-REFERENCE TO RELATED ORDERS
[001] This application claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 456271, filed March 31, 2023, which is incorporated herein by reference in its entirety. BACKGROUND
[002] Adiponectin is a hormone and an adipokine protein, produced mainly by adipose tissue, that has insulin-sensitizing and anti-inflammatory effects. Individuals with low adiponectin levels have a three times greater risk of developing metabolic syndrome and nine times greater chance of developing type 2 diabetes. Men with two or more risk factors for metabolic syndrome and high adiponectin levels are half as likely to develop metabolic syndrome compared to men with low adiponectin levels. Therefore, adiponectin has a significant effect on metabolic processes.
[003] A reliable and accurate method is needed to measure adiponectin levels. SUMMARY
[004] In one aspect, methods are provided for measuring adiponectin levels in a patient by determining the amount of adiponectin in a sample using mass spectrometry.
[005] In some embodiments, a method is provided for determining the amount of adiponectin in a sample by mass spectrometry, the method including: (a) subjecting adiponectin from a sample to an ionization source under suitable conditions to generate one or more adiponectin ions detectable by mass spectrometry; (b) determining the amount of one or more adiponectin ions Petition 870260109721, dated 10 / 23 / 2026, page 6 / 141 2 / 64 nectin by mass spectrometry; and (c) determine the amount of adiponectin in the sample from the amount of one or more adiponectin ions determined in step (b).
[006] In some embodiments, the quantity of one or more determined ions is used to determine the amount of adiponectin in the sample. In some embodiments, the amount of adiponectin in the sample is related to the amount of adiponectin in the patient.
[007] In some embodiments, the sample is a serum sample. In some embodiments, the sample is a plasma sample. In some embodiments, the sample is a blood, saliva, or urine sample.
[008] In some embodiments, ionization includes electrovaporization ionization (ESI). In some embodiments, ionization includes atmospheric pressure chemical ionization (APCI). In some embodiments, ionization is positive ion mode ionization. In some embodiments, ionization is positive ion mode ESI.
[009] In some embodiments, one or more adiponectin ions comprise a precursor ion having a mass-to-charge ratio (m / z) of 421.23 ± 0.5.
[0010] In some embodiments, one or more adiponectin ions comprise a fragment ion with a mass-to-charge ratio (m / z) of 314.18 ± 0.5. In some embodiments, one or more adiponectin fragment ions comprise an ion with a mass-to-charge ratio (m / z) of 627.36 ± 0.5. In some embodiments, one or more adiponectin fragment ions comprise an ion with a mass-to-charge ratio (m / z) of 530.30 ± 0.5.
[0011] In some embodiments, the methods provided herein comprise the addition of internal standards to the sample. In some embodiments, an internal standard for adiponectin is added to Petition 870260109721, dated 10 / 23 / 2026, page 7 / 141 3 / 64 sample. In some embodiments, the internal standard is recombinant human adiponectin or adiponectin peptides. In some embodiments, one or more ions of the internal standard comprise a precursor ion having a mass-to-charge ratio (m / z) of 416.22 ± 0.5. In some embodiments, one or more ions of the internal standard comprise a fragment ion with a mass-to-charge ratio (m / z) of 319.19 ± 0.5. In some embodiments, one or more ions of the internal standard comprise a fragment with a mass-to-charge ratio (m / z) of 637.37 ± 0.5. In some embodiments, one or more ions of the internal standard comprise a fragment with a mass-to-charge ratio (m / z) of 540.31 ± 0.5.
[0012] In some embodiments, the methods provided herein comprise digestion with trypsin. In some embodiments, the methods provided herein comprise precipitation with formic acid (e.g., precipitates deoxycholate with formic acid).
[0013] In some embodiments, the methods provided herein comprise the purification of samples prior to mass spectrometry. In some embodiments, the methods comprise the purification of samples by liquid chromatography. In some embodiments, liquid chromatography comprises high-performance liquid chromatography (HPLC) or high-turbulence liquid chromatography (HTLC). In some embodiments, the methods comprise subjecting a sample to solid-phase extraction (SPE).
[0014] In some modalities, the limit of quantification is less than 2.0 pg / mL. In some modalities, the limit of quantification is less than 1.0 pg / mL. In some modalities, the limit of quantification is less than 0.9 pg / mL.
[0015] In some modes, the detection limit is lower than 1.0 pg / mL. In some forms, the detection limit is less than 0.8 pg / mL. In some forms, the detection limit is less than Petition 870260109721, dated 10 / 23 / 2026, page 8 / 141 4 / 64 0.75 pg / mL.
[0016] In some embodiments, mass spectrometry comprises tandem mass spectrometry. In some embodiments, mass spectrometry is high-resolution mass spectrometry. In some embodiments, mass spectrometry is high-resolution / high-precision mass spectrometry.
[0017] In some modalities, a low level (e.g., below the established reference ranges described in Table 1) of adiponectin corresponds to an increased risk of metabolic syndrome. In some modalities, a low level (e.g., below the established reference ranges described in Table 1) of adiponectin corresponds to an increased risk of type 2 diabetes.
[0018] In some embodiments, the collision energy is within the range of about 5 V to about 25 V. In some embodiments, the collision energy is within the range of about 9 V to about 21 V. In some embodiments, the collision energy is about 9 V. In some embodiments, the collision energy is about 21 V.
[0019] In another aspect, methods are provided here for the diagnosis of glycemic disorders or insulin resistance syndromes in diabetic and pre-diabetic patients. In some embodiments, the endogenous adiponectin quantification methods provided here are used for the diagnosis of diabetes. In some embodiments, the endogenous adiponectin quantification methods provided here are used to distinguish type 1 diabetes from type 2 diabetes. In some embodiments, the endogenous adiponectin quantification methods provided here are used to assess the risk of diabetes in pre-diabetic patients.
[0020] In another aspect, methods are provided here for diag Petition 870260109721, dated 10 / 23 / 2026, p. 9 / 141 5 / 64 Diagnostic or prognostic methods for glycemic disorders or insulin resistance syndromes in diabetic and pre-diabetic patients, comprising the comparison of the relative amount of adiponectin. In another aspect, methods are provided here for the diagnosis or prognosis of glycemic disorders or insulin resistance syndromes in diabetic and pre-diabetic patients, comprising the determination of adiponectin levels. In some embodiments, the methods comprise the determination of the amount of adiponectin. In some embodiments, an aberrant or abnormal amount of adiponectin indicates glycemic disorders or insulin resistance syndromes. In some embodiments, a low level (e.g., below the established reference ranges described in Table 1) of adiponectin indicates glycemic disorders or insulin resistance syndromes.
[0021] The summary of the invention described above is not exhaustive, and other features and advantages of the invention will be apparent from the following detailed description of the invention and the claims. BRIEF DESCRIPTION OF THE FIGURES
[0022] FIGS. 1A-1B show that the comparison between the method The validated ELISA and LC / MS method produced a slope of 1.008 with an intercept of -0.167 (FIG. 1A) and a difference plot between ELISA and LC / MS (FIG. 1B).
[0023] FIGS. 2A-2C show that all three QC levels meet the acceptance criteria for total precision of TEa / 3 at low (FIG. 2A), medium (FIG. 2B) and high (FIG. 2C).
[0024] FIG. 3 shows that the acceptance criteria were met across the entire AMR from 1.50 pg / mL to 50.00 pg / mL.
[0025] FIGS. 4A-4B show that carryover and pre-carryover did not exceed TEa / 4 for adiponectin, thus passing the acceptance criteria in LC3 (FIG. 4A) and in LC4 (FIG. 4B). Petition 870260109721, dated 10 / 23 / 2026, p. 10 / 141 6 / 64
[0026] FIG. 5 shows that the LOB was calculated at 0.419 pg / mL, the LOD at 0.740 pg / mL and LOQ at 0.831 pg / mL. Each of the low-value pools showed SD < TEa / 3 and met the acceptance criteria.
[0027] FIG. 6 shows that the average concentration was within TEa / 3 of the average concentration measured at t = 0 for all time points evaluated.
[0028] FIG. 7 shows that the average concentration was within TEa / 3 of the average concentration measured at t = 0 for all time points evaluated.
[0029] FIG. 8 shows that the average concentration was within TEa / 3 of the average concentration measured at t = 0 for all time points up to 20 days.
[0030] FIGS. 9A-9B show that the average concentration was within TEa / 3 of the average concentration measured at t = 0 for all evaluated time points from -20 to -40 °C (FIG. 9A) and at -70 °C (FIG. 9B).
[0031] FIG. 10 shows that the average concentration was within TEa / 3 of the average concentration measured at t = 0 for all freeze / thaw cycles evaluated.
[0032] FIGS. 11A-11B show plate stability (cold stack) with adiponectin comparison (FIG. 11A) and adiponectin difference graph (FIG. 11B).
[0033] FIGS. 12A-12B show hemolysis interference (FIG. 12A) and hemolysate (FIG. 12B).
[0034] FIGS. 13A-13B show interference of jaundice (bilirubin) (FIG. 13A) and bilirubin (FIG. 13B).
[0035] FIGS. 14A-14B show lipemia interference (intralipid) (FIG. 14A) and intralipid (FIG. 14B). DETAILED DESCRIPTION Petition 870260109721, dated 10 / 23 / 2026, p. 11 / 141 7 / 64
[0036] As used herein, unless otherwise indicated, the singular forms a, an, an and the include reference to the plural. Thus, for example, a reference to a protein includes a plurality of protein molecules.
[0037] As used herein, the terms purification, purify, and enrichment do not refer to the removal of all sample materials except the analyte(s) of interest. Instead, these terms refer to a procedure that enriches the amount of one or more analytes of interest relative to other sample components that may interfere with the detection of the analyte of interest. Sample purification by various means may allow for the relative reduction of one or more interfering substances, for example, one or more substances that may or may not interfere with the detection of parent or daughter ions selected by mass spectrometry. Relative reduction, as used in this term, does not require that any substance present in the analyte of interest in the material to be purified be completely removed by purification.
[0038] As used herein, the term immunopurification or immunopurify refers to a purification procedure that uses antibodies, including polyclonal or monoclonal antibodies, to enrich one or more analytes of interest. Immunopurification can be performed using any of the immunopurification methods well known in the art. Frequently, the immunopurification procedure uses antibodies bound, conjugated, or otherwise fixed to a solid support, for example, a column, cavity, tube, gel, capsule, particle, or similar. Immunopurification, as used herein, includes, without limitation, procedures frequently referred to in the art as immunoprecipitation, as well as procedures frequently referred to in the art as affinity chromatography or immunoaffinity chromatography. Petition 870260109721, dated 10 / 23 / 2026, page 12 / 141 8 / 64
[0039] As used herein, the term immunoparticle refers to a capsule, bead, gel particle or similar that has antibodies bound, conjugated or otherwise fixed to its surface (either on and / or in the particle). In certain preferred embodiments, the immunoparticles are sepharose or agarose beads. In alternative preferred embodiments, the immunoparticles comprise glass, plastic or silica beads, or silica gel.
[0040] As used herein, the term anti-adiponectin antibody refers to any polyclonal or monoclonal antibody that has affinity for adiponectin. In various embodiments, the specificity of anti-adiponectin antibodies for chemical species other than adiponectin may vary; for example, in certain preferred embodiments, anti-adiponectin antibodies are specific for adiponectin and therefore have little or no affinity for chemical species other than adiponectin.
[0041] As used herein, the term sample refers to any sample that may contain an analyte of interest. As used herein, the term body fluid means any fluid that can be isolated from an individual's body. For example, body fluid may include blood, plasma, serum, bile, saliva, urine, tears, sweat, and the like. In preferred embodiments, the sample comprises a sample of human body fluid; preferably plasma or serum.
[0042] As used herein, the term solid-phase extraction or SPE refers to a process in which a chemical mixture is separated into components as a result of the affinity of the components dissolved or suspended in a solution (i.e., mobile phase) for a solid through or around which the solution is passed (i.e., solid phase). In some cases, as the mobile phase passes through or around the solid phase, unwanted components of the mobile phase may be retained by the solid phase, resulting in the purification of the analyte in the solid phase. Petition 870260109721, dated 10 / 23 / 2026, p. 13 / 141 9 / 64 mobile. In other cases, the analyte may be retained by the solid phase, allowing unwanted components of the mobile phase to pass through or around the solid phase. In these cases, a second mobile phase is then used to elute the retained analyte from the solid phase for further processing or analysis. SPE, including TFLC, can operate via a single-mode or mixed-mode mechanism. Mixed-mode mechanisms use ion exchange and hydrophobic retention in the same column; for example, the solid phase of a mixed-mode SPE column may exhibit strong anion exchange and hydrophobic retention; or it may exhibit strong cation exchange and hydrophobic retention.
[0043] Generally, the affinity of an SPE column packing material for an analyte can be due to a variety of mechanisms, such as one or more chemical interactions or an immunoaffinity interaction. In some embodiments, adiponectin SPE is conducted without the use of an immunoaffinity column packing material. That is, in some embodiments, adiponectin is purified from a sample by an SPE column that is not an immunoaffinity column.
[0044] As used herein, the term chromatography refers to a process in which a chemical mixture carried by a liquid or gas is separated into components as a result of the differential distribution of the chemical entities as they flow around or over a stationary liquid or solid phase.
[0045] As used herein, the term liquid chromatography or LC means a process of selective retardation of one or more components of a fluid solution as the fluid percolates uniformly through a column of finely divided substance or through capillary passages. The retardation results from the distribution of the mixture components between one or more stationary phases and the bulk fluid (i.e., mobile phase) as this fluid moves in relation to the fluid. Petition 870260109721, dated 10 / 23 / 2026, page 14 / 141 10 / 64 tion to the stationary phase(s). Examples of liquid chromatography include reversed-phase liquid chromatography (RPLC), high-performance liquid chromatography (HPLC), and turbulent flow liquid chromatography (TFLC) (sometimes known as high-turbulence liquid chromatography (HTLC) or high-throughput liquid chromatography).
[0046] As used herein, the term high-performance liquid chromatography or HPLC (sometimes known as high-pressure liquid chromatography) refers to liquid chromatography in which the degree of separation is increased by forcing the mobile phase under pressure through a stationary phase, typically a densely packed column.
[0047] As used herein, the term turbulent flow liquid chromatography or TFLC (sometimes known as high-turbulence liquid chromatography or high-throughput liquid chromatography) refers to a form of chromatography that uses the turbulent flow of the material to be analyzed through the column packing as the basis for performing the separation. TFLC has been applied in the preparation of samples containing two unnamed drugs prior to analysis by mass spectrometry. See, for example, Zimmer et al., J Chromatogr A 854: 23-35 (1999); see also, U.S. Patents Nos. 5,968,367, 5,919,368, 5,795,469, and 5,772,874, which explain TFLC in more detail. People with common knowledge of the technique understand turbulent flow. When the fluid flows slowly and smoothly, the flow is called laminar flow. For example, the fluid moving through an HPLC column at low flow rates is laminar.In laminar flow, the movement of fluid particles is ordered, with particles generally moving in substantially straight lines. At faster speeds, the inertia of the water overcomes the frictional forces of the fluid, resulting in turbulent flow. The fluid that is not in contact with the irregular boundary overtakes that which is slowed down by friction. Petition 870260109721, dated 10 / 23 / 2026, page 15 / 141 11 / 64 to or deflected by an irregular surface. When a fluid is flowing turbulently, it flows in eddies and swirls (or vortices), with more drag than when the flow is laminar. Many references are available to assist in determining when fluid flow is laminar or turbulent (e.g., Turbulent Flow Analysis: Measurement and Prediction, PS Bernard & JM Wallace, John Wiley & Sons, Inc., (2000); An Introduction to Turbulent Flow, Jean Mathieu & Julian Scott, Cambridge University Press (2001)).
[0048] As used herein, the term gas chromatography or GC refers to chromatography in which the sample mixture is vaporized and injected into a stream of carrier gas (such as nitrogen or helium) that moves through a column containing a stationary phase composed of a liquid or a particulate solid and is separated into its component compounds according to the affinity of the compounds for the stationary phase.
[0049] As used herein, the term large particle column or extraction column refers to a chromatographic column containing an average particle diameter greater than about 50 μm. As used in this context, the term about means ± 10%.
[0050] As used herein, the term analytical column refers to a chromatographic column with sufficient chromatographic plates to effect the separation of materials in a sample that elute from the column in sufficient quantity to permit the determination of the presence or quantity of an analyte. Such columns are often distinguished from extraction columns, which have the general purpose of separating or extracting retained material from non-retained materials to obtain a purified sample for further analysis. As used in this context, the term about means ± 10%. In a preferred embodiment, the analytical column contains particles approximately 5 µm in diameter. Petition 870260109721, dated 10 / 23 / 2026, page 16 / 141 12 / 64
[0051] As used herein, the terms online and inline, for example, as used in automated online mode or online extraction, refer to a procedure performed without the need for operator intervention. In contrast, the term offline, as used herein, refers to a procedure that requires manual operator intervention. Thus, if samples are subjected to precipitation and the supernatants are then manually loaded into an autosampler, the precipitation and loading steps will be performed offline with respect to subsequent steps. In several embodiments of the methods, one or more steps may be performed in an automated online manner.
[0052] As used herein, the term mass spectrometry or EM refers to an analytical technique for identifying compounds by their mass. EM refers to methods of filtering, detecting, and measuring ions based on their mass-to-charge ratio, or m / z. EM technology generally includes (1) ionizing compounds to form charged compounds; and (2) detecting the molecular weight of the charged compounds and calculating a mass-to-charge ratio. Compounds can be ionized and detected by any suitable means. A mass spectrometer generally includes an ionizer, a mass analyzer, and an ion detector. In general, one or more molecules of interest are ionized, and the ions are subsequently introduced into a mass spectrometry instrument where, due to a combination of magnetic and electric fields, the ions follow a path in space that depends on mass (m) and charge (z). See, for example, U.S. Patents No. 6,204,500, entitled Mass Spectrometry From Surfaces; 6,107.623, intitulado Methods and Apparatus for Tandem Mass Spectrometry; 6.268.144, intitulado DNA Diagnostics Based On Mass Spectrometry; 6.124.137, intitulado Surface-Enhanced Photolabile Attachment And Release For Desorp. Petição 870260109721, de 23 / 10 / 2026, pág. 17 / 141 13 / 64 tion And Detection Of Analytes; Wright et al., Prostate Cancer and Prostatic Diseases 1999, 2: 264-76; and Merchant and Weinberger, Electrophoresis 2000, 21: 1164-67.
[0053] As used herein, high-resolution / high-precision mass spectrometry refers to mass spectrometry conducted with a mass analyzer capable of measuring the mass-to-charge ratio of a charged species with sufficient precision and accuracy to confirm a specific chemical ion. Confirmation of a specific chemical ion is possible for an ion when individual isotopic peaks of that ion are readily discernible. The specific resolving power and mass precision required to confirm a specific chemical ion vary with the mass and charge state of the ion.
[0054] As used herein, the term resolving power or resolving power (FWHM) (also known in the art as m / Δm50%) refers to the observed mass-to-charge ratio divided by the width of the mass peak at 50% of the maximum height (Full Width Half Maximum, FWHM). The effect of differences in resolving power is illustrated in Figures 1A-C, which show theoretical mass spectra of an ion with am / z of about 1093. Figure 1A shows a theoretical mass spectrum from a mass analyzer with a resolving power of about 3000 (a typical operating condition for a conventional quadrupole mass analyzer). As seen in Figure 1A, no individual isotopic peaks are discernible. In comparison, Figure 1B shows a theoretical mass spectrum from a mass analyzer with a resolving power of about 10,000, with clearly discernible individual isotopic peaks. Figure 1C shows a theoretical mass spectrum from a mass analyzer with a resolving power of approximately 12,000.At this maximum resolving power, individual isotopic peaks contain less than 1% baseline contribution. Petition 870260109721, dated 10 / 23 / 2026, page 18 / 141 14 / 64
[0055] As used herein, single chemical ion in relation to mass spectrometry refers to a single ion with a single atomic composition. The ion may have single or multiple charges.
[0056] As used herein, the term precision (or mass precision) with respect to mass spectrometry refers to the potential deviation of the instrument response from the actual m / z of the ion being investigated. Precision is typically expressed in parts per million (ppm). The effect of differences in mass precision is illustrated in Figures 2A-D, which show the limits of the potential differences between a detected m / z and an actual m / z for a theoretical peak at m / z of 1093.52094. Figure 2A shows the potential range of the detected m / z with a precision of 120 ppm. In contrast, Figure 2B shows the potential range of the detected m / z with a precision of 50 ppm. Figures 2C and 2D show the even narrower potential ranges of the detected m / z with precisions of 20 ppm and 10 ppm.
[0057] The high-resolution / high-precision mass spectrometry methods of the present invention can be conducted on instruments capable of performing mass analyses with FWHM greater than 10,000, 15,000, 20,000, 25,000, 50,000, 100,000 or even more. Similarly, the methods of the present invention can be conducted on instruments capable of performing mass analyses with precision less than 50 ppm, 20 ppm, 15 ppm, 10 ppm, 5 ppm, 3 ppm or even less. Instruments with these performance characteristics may incorporate certain orbitrap mass analyzers, time-of-flight (TOF) mass analyzers, or Fourier transform ion cyclotron resonance mass analyzers. In preferred embodiments, the methods are conducted with an instrument that includes an orbitrap mass analyzer or a TOF mass analyzer.
[0058] The term orbitrap describes an ion trap that Petition 870260109721, dated 10 / 23 / 2026, p. 19 / 141 The 15 / 64 consists of an outer barrel-shaped electrode and an inner coaxial electrode. Ions are injected tangentially into the electric field between the electrodes and trapped because the electrostatic interactions between the ions and the electrodes are balanced by centrifugal forces as the ions orbit the inner coaxial electrode. As an ion orbits the inner coaxial electrode, the orbital path of a trapped ion oscillates along the axis of the central electrode at a harmonic frequency relative to the ion's mass-to-charge ratio. Detection of the orbital oscillation frequency allows the orbitrap to be used as a mass analyzer with high precision (as low as 1-2 ppm) and high resolving power (FWHM) (up to about 200,000). A mass analyzer based on an orbitrap is described in detail in U.S. Patent No. 6,995,364, which is incorporated herein by reference in its entirety.The use of orbitrap analyzers has been reported for qualitative and quantitative analyses of various analytes. See, for example, U.S. Patent Application Pub. No. 2008 / 0118932 (filed November 9, 2007); Bredehoft, et al., Rapid Commun. Mass Spectrom., 2008, 22:477-485; Le Breton, et al., Rapid Commun. Mass Spectrom., 2008, 22:3130-36; Thevis, et al., Mass Spectrom. Reviews, 2008, 27:35-50; Thomas, et al., J. Mass Spectrom., 2008, 43:908-15; Schenk, et al., BMC Medical Genomics, 2008, 1:41; and Olsen, et al., Nature Methods, 2007, 4:709-12.
[0059] As used herein, the term operating in negative ion mode refers to mass spectrometry methods in which negative ions are generated and detected. The term operating in positive ion mode, as used herein, refers to mass spectrometry methods in which positive ions are generated and detected. In preferred embodiments, mass spectrometry is conducted in positive ion mode.
[0060] As used herein, the term ionization or ionize refers to Petition 870260109721, dated 10 / 23 / 2026, page 20 / 141 16 / 64 refers to the process of generating an analyte ion with a net electrical charge equal to one or more electronic units. Negative ions are those with a net negative charge of one or more electronic units, while positive ions are those with a net positive charge of one or more electronic units.
[0061] As used herein, the term electronic ionization or EI refers to methods in which an analyte of interest, in the gas or vapor phase, interacts with a stream of electrons. The impact of the electrons with the analyte produces ions, which can then be subjected to a mass spectrometry technique.
[0062] As used herein, the term chemical ionization or CI refers to methods in which a reactant gas (e.g., ammonia) is subjected to electron impact, and analyte ions are formed by the interaction of reactant gas ions and analyte molecules.
[0063] As used here, the term rapid atomic bombardment or FAB refers to methods in which a beam of high-energy atoms (usually Xe or Ar) impacts a non-volatile sample, desorbing and ionizing the molecules contained in the sample. Test samples are dissolved in a viscous liquid matrix, such as glycerol, thioglycerol, m-nitrobenzyl alcohol, 18-crown-6-crown ether, 2-nitrophenyloctyl ether, sulfolane, diethanolamine, and triethanolamine. The choice of an appropriate matrix for a compound or sample is an empirical process.
[0064] As used herein, the term matrix-assisted laser desorption / ionization or MALDI refers to methods in which a non-volatile sample is exposed to laser irradiation, which desorbs and ionizes the analytes present in the sample through various ionization pathways, including photoionization, protonation, deprotonation, and cluster decay. For MALDI, the sample is mixed with an energy-absorbing matrix, which facilitates the desorption of the molecules from Petition 870260109721, dated 10 / 23 / 2026, page 21 / 141 17 / 64 analyte.
[0065] As used herein, the term surface-enhanced laser desorption ionization or SELDI refers to another method in which a non-volatile sample is exposed to laser irradiation, which desorbs and ionizes the analytes present in the sample through various ionization pathways, including photoionization, protonation, deprotonation, and cluster decay. For SELDI, the sample is typically attached to a surface that preferably retains one or more analytes of interest. As with MALDI, this process may also employ an energy-absorbing material to facilitate ionization.
[0066] As used herein, the term electrovaporization ionization or ESI refers to methods in which a solution is passed along a small capillary tube, at the end of which a high electrical potential, positive or negative, is applied. The solution that reaches the end of the tube is vaporized (nebulized) into a jet or spray of very small droplets of solution in solvent vapor. This mist of droplets flows through an evaporation chamber. As the droplets shrink, the electrical charge density of the surface increases until the natural repulsion between like charges causes the release of ions and neutral molecules.
[0067] As used herein, the term atmospheric pressure chemical ionization or APCI refers to mass spectrometry methods similar to ESI; however, APCI produces ions through ion-molecule reactions occurring within a plasma at atmospheric pressure. The plasma is maintained by an electrical discharge between the spray capillary and a counter electrode. The ions are then typically extracted to the mass analyzer via a set of differentially pumped skimmer stages. A counterflow of dry, preheated N2 gas may be used to improve solvent removal. Gas-phase ionization in APCI Petition 870260109721, dated 10 / 23 / 2026, page 22 / 141 18 / 64 may be more effective than ESI for analyzing less polar species.
[0068] The term atmospheric pressure photoionization or APPI, as used herein, refers to the form of mass spectrometry in which the mechanism for the ionization of molecule M is the absorption of photons and the ejection of electrons to form the molecular ion M+. Because the photon energy is typically just above the ionization potential, the molecular ion is less susceptible to dissociation. In many cases, it may be possible to analyze samples without the need for chromatography, saving significant time and expense. In the presence of water vapor or protic solvents, the molecular ion can extract H+ to form MH+. This tends to occur if M has a high affinity for protons. This does not affect the accuracy of quantification because the sum of M+ and MH+ is constant. Drug compounds in protic solvents are generally observed as MH+, while nonpolar compounds, such as naphthalene or testosterone, generally form M+. See, for example, Robb et al., Anal. Chem. 2000, 72(15): 3653-3659.
[0069] As used herein, the term inductively coupled plasma or ICP refers to methods in which a sample interacts with a partially ionized gas at a temperature high enough that most of the elements are atomized and ionized.
[0070] As used herein, the term field desorption refers to methods in which a non-volatile test sample is placed on an ionization surface and an intense electric field is used to generate analyte ions.
[0071] As used herein, the term desorption refers to the removal of an analyte from a surface and / or the entry of an analyte into a gas phase. Laser desorption (thermal desorption) is a technique in which a sample containing the analyte is thermally desorbed into the gas phase by means of a laser pulse. The laser strikes the Petition 870260109721, dated 10 / 23 / 2026, page 23 / 141 19 / 64 rear section of a specially manufactured 96-cavity plate with a metal base. The laser pulse heats the base, and the heat causes the sample to be transferred to the gas phase. The gas-phase sample is then aspirated into the mass spectrometer.
[0072] As used herein, the term selective ion monitoring is a detection mode for a mass spectrometry instrument in which only ions within a relatively narrow mass range, typically about one mass unit, are detected.
[0073] As used herein, multiple reaction mode, sometimes known as selective reaction monitoring, is a detection mode for a mass spectrometry instrument in which a precursor ion and one or more fragment ions are selectively detected.
[0074] As used herein, the term lower limit of quantification, lower limit of quantification or LLOQ refers to the point at which measurements become quantitatively significant. The analyte response at this LOQ is identifiable, discrete, and reproducible, with a relative standard deviation (RSD %) of less than 20% and a precision of 85% to 115%.
[0075] As used herein, the term limit of detection or LOD refers to the point at which the measured value is greater than the uncertainty associated with it. LOD is the point at which a value is beyond the uncertainty associated with its measurement and is defined as three times the standard deviation (RDA) of the mean at zero concentration.
[0076] As used herein, an amount of an analyte in a body fluid sample generally refers to an absolute value reflecting the mass of the analyte detectable in the sample volume. However, an amount also encompasses a relative quantity compared to the amount of another analyte. For example, an Petition 870260109721, dated 10 / 23 / 2026, page 24 / 141 20 / 64 The amount of an analyte in a sample may be greater than a control or normal level of the analyte that is normally present in the sample.
[0077] The term about, as used herein in reference to quantitative measurements that do not include the measurement of the mass of an ion, refers to the indicated value plus or minus 10%. Mass spectrometry instruments may vary slightly in determining the mass of a given analyte. The term about, in the context of the mass of an ion or the mass-to-charge ratio of an ion, refers to + / - 0.50 atomic mass units.
[0078] In one aspect, methods are provided here for measuring adiponectin levels in a patient by determining the amount of adiponectin in a sample using mass spectrometry.
[0079] The methods may be for determining the amount of adiponectin in a sample by mass spectrometry, the method comprising: (a) subjecting adiponectin from a sample to an ionization source under suitable conditions to generate one or more adiponectin ions detectable by mass spectrometry; (b) determining the amount of one or more adiponectin ions by mass spectrometry; and (c) determining the amount of adiponectin in the sample from the amount of one or more adiponectin ions determined in step (b).
[0080] The quantity of one or more ions determined can then be used to determine the amount of adiponectin in the sample. In some embodiments, the amount of adiponectin in the sample is related to the amount of adiponectin in the patient.
[0081] The sample may be a serum sample. In some embodiments, the sample is a plasma sample. In other embodiments, the sample is a blood, saliva, or urine sample.
[0082] Ionization may include ionization by electrovaporization Petition 870260109721, dated 10 / 23 / 2026, page 25 / 141 21 / 64 (ESI). In some modes, ionization includes atmospheric pressure chemical ionization (APCI). In some modes, ionization occurs in positive ion mode. In some modes, ionization is ESI in positive ion mode.
[0083] One or more adiponectin ions may include a precursor ion with a mass-to-charge ratio (m / z) of 421.23 ± 0.5. One or more adiponectin ions may also include a fragment ion with a mass-to-charge ratio (m / z) of 314.18 ± 0.5. In some embodiments, one or more adiponectin fragment ions may include an ion with a mass-to-charge ratio (m / z) of 627.36 ± 0.5. In some embodiments, one or more adiponectin fragment ions may include an ion with a mass-to-charge ratio (m / z) of 530.30 ± 0.5.
[0084] The methods provided herein may include the addition of internal standards to the sample. The internal standard for adiponectin may be added to the sample. In some embodiments, the internal standard is recombinant human adiponectin or adiponectin peptides. The methods may also include the generation of one or more internal standard ions that are detectable by mass spectrometry. One or more internal standard ions may include a precursor ion that has a mass-to-charge ratio (m / z) of 416.22 ± 0.5. In some embodiments, one or more internal standard ions may include a fragment ion with a mass-to-charge ratio (m / z) of 319.19 ± 0.5. In some embodiments, one or more internal standard ions may include a fragment with a mass-to-charge ratio (m / z) of 637.37 ± 0.5. In some embodiments, one or more ions of the internal standard may include a fragment with a mass-to-charge ratio (m / z) of 540.31 ± 0.5.
[0085] The methods provided here may include the digestion of adiponectin in the sample. Digestion can be performed using trypsi Petition 870260109721, dated 10 / 23 / 2026, page 26 / 141 22 / 64 in some embodiments. In addition, the methods may include subjecting the sample (e.g., a solution) containing adiponectin (and / or an adiponectin digestion product) to precipitation (e.g., precipitating deoxycholate with formic acid). In some embodiments, the sample (e.g., the solution) containing adiponectin (and / or an adiponectin digestion product) may be purified by precipitation (e.g., precipitation with formic acid).
[0086] The methods provided here can also purify samples prior to mass spectrometry. Such purification can be performed by liquid chromatography, which in some embodiments may be high-performance liquid chromatography (HPLC) or high-turbulence liquid chromatography (HTLC). The methods may also include subjecting a sample to solid-phase extraction (SPE).
[0087] Various mass spectrometry techniques can be used, such as tandem mass spectrometry, high-resolution mass spectrometry, or high-resolution / high-precision mass spectrometry.
[0088] The methods may predict a limit of quantification lower than 2.0 pg / mL. This may include situations where the method's limit of quantification is lower than 1.0 pg / mL, lower than 0.9 pg / mL, lower than 0.8 pg / mL, or lower than 0.75 pg / mL, according to various embodiments.
[0089] Low adiponectin levels may correspond to an increased risk of metabolic syndrome. For example, a low adiponectin level may correspond to an increased risk of type 2 diabetes. As used herein, the term low level (e.g., a low adiponectin level) generally refers to an amount that is below the established reference range of an analyte, as determined from a cohort of apparently healthy individuals. For example, without being limited by theory, it is believed Petition 870260109721, dated 10 / 23 / 2026, page 27 / 141 23 / 64 that the adiponectin reference ranges are those shown in Table 1, which are classified by patient sex and body mass index (BMI). Table 1. Reference ranges for adiponectin in healthy individuals. BMI Male Female <25 kg / m2 4 to 26 pg / mL 5 to 37 pg / mL 25 to 30 kg / m2 4 to 20 pg / mL 5 to 28 pg / mL >30 kg / m2 2 to 20 pg / mL 4 to 22 pg / mL
[0090] In some embodiments, the collision energy used in a method is from about 5 V to about 25 V. This may include when the collision energy is from about 9 V to about 21 V, is about 9 V, or is about 21 V.
[0091] In another aspect, methods for diagnosing glycemic disorders or insulin resistance syndromes in diabetic and pre-diabetic patients are presented. Such methods for quantifying endogenous adiponectin can be used to diagnose diabetes or to distinguish type 1 diabetes from type 2 diabetes. In some modalities, methods for quantifying endogenous adiponectin are used to assess the risk of diabetes in pre-diabetic patients.
[0092] In another aspect, methods are provided for the diagnosis or determination of the prognosis of glycemic disorders or insulin resistance syndromes in diabetic and prediabetic patients. Such methods may include comparing the relative amount of adiponectin (for example, comparing the amount of adiponectin in a patient with the corresponding reference described in Table 1).
[0093] In another aspect, methods are provided for the diagnosis or determination of the prognosis of glycemic disorders or insulin resistance syndromes in diabetic and pre-diabetic patients. Petition 870260109721, dated 10 / 23 / 2026, page 28 / 141 24 / 64 diabetics. Such methods include determining adiponectin levels in a sample from an individual. The methods may include determining the amount of adiponectin. In some modalities, an aberrant or abnormal amount of adiponectin indicates glycemic disorders or insulin resistance syndromes. In other modalities, a low level (e.g., below the established references described in Table 1) of adiponectin indicates glycemic disorders or insulin resistance syndromes.
[0094] In a further aspect, kits are provided for an adiponectin quantification assay. A kit for an adiponectin quantification assay may include a kit comprising the compositions provided herein. For example, a kit may include packaging material and measured quantities of an isotopically labeled internal standard, in sufficient quantities for at least one assay. Typically, the kits will also include recorded instructions in a tangible format (e.g., contained in paper or electronic media) for the use of the packaged reagents for use in an adiponectin quantification assay.
[0095] Calibration and QC (quality control) pools for use in embodiments of the present invention are preferably prepared using a matrix similar to the matrix of the intended sample, provided that adiponectin is essentially absent. Sample preparation for mass spectrometric analysis
[0096] In preparation for mass spectrometric analysis, adiponectin can be enriched with respect to one or more other components in the sample by various methods known in the art, including, for example, immunocapture, liquid chromatography, filtration, centrifugation, thin-layer chromatography (TLC), electrophoresis including capillary electrophoresis, affinity separations including immunoaffinity separations, extraction methods including extraction with Petition 870260109721, dated 10 / 23 / 2026, page 29 / 141 25 / 64 ethyl acetate or methanol and the use of chaotropic agents or any combination of the foregoing or similar agents.
[0097] A sample purification method that can be used prior to mass spectrometry is the application of a sample to a solid-phase extraction (SPE) column under conditions where the analyte of interest is reversibly retained by the column packing material, while one or more other materials are not retained. In this technique, a first mobile phase condition can be employed, in which the analyte of interest is retained by the column, and a second mobile phase condition can be subsequently employed to remove the retained material from the column, after washing away the non-retained materials.
[0098] In some embodiments, adiponectin in a sample can be reversibly retained on an SPE column with a packing material comprising an alkyl-bonded surface. For example, in some embodiments, a C-8 online SPE column (such as a Phenomenex, Inc. Oasis HLB (2.1 mm x 20 mm) online SPE column / cartridge or equivalent) can be used to enrich adiponectin prior to mass spectrometric analysis. In some embodiments, the use of an SPE column is conducted with 0.2% aqueous HPLC-grade formic acid as the washing solution and 0.2% formic acid in acetonitrile as the elution solution.
[0099] In other embodiments, the methods include immunopurification of adiponectin prior to mass spectrometry analysis. The immunopurification step can be performed using any of the well-known immunopurification methods in the art. Frequently, the immunopurification procedure uses antibodies that are bound, conjugated, immobilized, or otherwise fixed to a solid support, for example, a column, cavity, tube, capsule, particle, or similar. Generally, immunopurification methods involve Petition 870260109721, dated 10 / 23 / 2026, page 30 / 141 26 / 64 involves (1) incubating a sample containing the analyte of interest with antibodies so that the analyte binds to the antibodies, (2) performing one or more washing steps, and (3) eluting the analyte from the antibodies.
[00100] In some embodiments, the incubation step of immunopurification is performed with the free antibodies in solution, which are subsequently bound or fixed to a solid surface before the washing steps. In some embodiments, this can be achieved using a primary antibody, which is an anti-adiponectin antibody, and a secondary antibody, fixed to a solid surface, that has affinity for the primary anti-adiponectin antibody. In alternative embodiments, the primary antibody is bound to the solid surface before the incubation step.
[00101] Suitable solid supports include, without limitation, tubes, slides, columns, beads, capsules, particles, gels, and the like. In some preferred embodiments, the solid support is a multi-well plate, such as, for example, a 96-well plate, a 384-well plate, or the like. In some embodiments, the solid support is sepharose or agarose beads or gels. There are numerous well-known methods in the art by which antibodies (e.g., an adiponectin antibody or a secondary antibody) can be linked, fixed, immobilized, or coupled to a solid support, for example, covalent or non-covalent bonding, adsorption, affinity binding, ionic bonding, and the like. In some embodiments, antibodies are coupled using CNBr; for example, antibodies can be coupled to CNBr-activated sepharose.In other embodiments, the antibody is fixed to the solid support by means of an antibody-binding protein, such as protein A, protein G, protein A / G, or protein L.
[00102] The washing step in immunopurification methods generally involves washing the solid support so that the adipoPetition 870260109721, dated 10 / 23 / 2026, page 31 / 141 27 / 64 Nectin remains bound to anti-adiponectin antibodies present on the solid support. The elution step of immunopurification generally involves the addition of a solution that disrupts the binding of adiponectin to anti-adiponectin antibodies. Exemplary elution solutions include organic solutions, saline solutions, and high or low pH solutions.
[00103] Another sample purification method that can be used prior to mass spectrometry is liquid chromatography (LC). In liquid chromatography techniques, an analyte can be purified by applying a sample to a chromatographic analytical column under mobile phase conditions, where the analyte of interest elutes at a different rate compared to one or more other materials. Such procedures can enrich the amount of one or more analytes of interest relative to one or more other components of the sample.
[00104] Certain liquid chromatography methods, including HPLC, rely on relatively slow laminar flow technology. Traditional HPLC analysis relies on column packing, in which the laminar flow of the sample through the column is the basis for the separation of the analyte of interest from the sample. The skilled technician will understand that separation in such columns is a partitioning process and can select LC instruments and columns, including HPLC, that are suitable for use with adiponectin. The analytical chromatographic column typically includes a medium (i.e., a packing material) to facilitate the separation of chemical fractions (i.e., fractionation). The medium may include minute particles. The particles typically include a bonded surface that interacts with the various chemical moieties to facilitate the separation of the chemical fractions. A suitable bonded surface is a hydrophobic bonded surface, such as an alkyl or cyano-bonded surface.Surfaces bonded by alkyl. Petition 870260109721, dated 10 / 23 / 2026, p. 32 / 141 28 / 64 la may include alkyl groups linked by C-4, C-8, C-12, or C-18. In some embodiments, the chromatographic analytical column is a monolithic C-18 column. The chromatographic analytical column includes an inlet port to receive a sample and an outlet port to discharge an effluent that includes the fractionated sample. The sample may be supplied directly to the inlet port or from an SPE column, such as an online SPE column or a TFLC column. In some embodiments, an online filter may be used before the SPE column and / or HPLC column to remove particles and phospholipids in the samples before they reach the SPE and / or TFLC and / or HPLC columns.
[00105] In one embodiment, the sample can be applied to the LC column at the inlet port, eluted with a solvent or solvent mixture, and discharged at the outlet port. Different solvent modes can be selected to elute the analyte(s) of interest. For example, liquid chromatography can be performed using a gradient mode, an isocratic mode, or a polytypic (i.e., mixed) mode. During chromatography, the separation of materials is affected by variables such as the choice of eluent (also known as mobile phase), elution mode, gradient conditions, temperature, etc.
[00106] Diponectin in a sample can be purified by HPLC. This HPLC can be conducted with a C-18 monolithic column chromatographic system, for example, an Onyx Monolithic C-18 column from Phenomenex Inc. (50 x 2.0 mm) or equivalent. In certain embodiments, HPLC is performed using 0.2% aqueous HPLC-grade formic acid as solvent A and 0.2% formic acid in acetonitrile as solvent B.
[00107] By selecting appropriate valves and connections, two or more chromatographic columns can be connected as needed, so that the material passes from one to the other without the Petition 870260109721, dated 10 / 23 / 2026, page 33 / 141 29 / 64 eliminates the need for manual steps. Valve and connection selection can be controlled by a pre-programmed computer to perform the necessary steps. The chromatographic system can also be connected online to a detector system, for example, a mass spectrometry system. Thus, an operator can place a sample tray in an autosampler, and the remaining operations are performed under computerized control, resulting in the purification and analysis of all selected samples.
[00108] In some embodiments, TFLC can be used for adiponectin purification prior to mass spectrometry. In such embodiments, samples can be extracted using a TFLC column that captures the analyte. The analyte is then eluted and transferred online to an HPLC analytical column. For example, sample extraction can be performed with a TFLC extraction cartridge with a large particle packing (50 μm). The sample eluted from this column can then be transferred online to an HPLC analytical column for further purification prior to mass spectrometry. Because the steps involved in these chromatographic procedures can be automated, the need for operator involvement during analyte purification can be minimized. This feature can result in time and cost savings, as well as eliminating the possibility of operator error.
[00109] In some embodiments, one or more of the above purification techniques can be used in parallel for the purification of adiponectin, allowing the simultaneous processing of multiple samples. In some embodiments, the purification techniques employed exclude immunopurification techniques, such as immunoaffinity chromatography. Detection and quantification of adiponectin by mass spectrometry. Petition 870260109721, dated 10 / 23 / 2026, page 34 / 141 30 / 64 sa
[00110] Mass spectrometry is performed using a mass spectrometer, which includes an ion source to ionize the fractionated sample and create charged molecules for further analysis. In various embodiments, adiponectin can be ionized by any method known to a technician skilled in the art. For example, adiponectin ionization can be performed by electronic ionization, chemical ionization, electrovaporization ionization (ESI), photon ionization, atmospheric pressure chemical ionization (APCI), photoionization, atmospheric pressure photoionization (APPI), laser diode thermal desorption (LDTD), fast atom bombardment (FAB), liquid secondary ionization (LSI), matrix-assisted laser desorption ionization (MALDI), field ionization, field desorption, thermovaporization / plasma vaporization ionization, surface-enhanced laser desorption ionization (SELDI), inductively coupled plasma (ICP), and particle beam ionization.Based on the analyte to be measured, the sample type, the detector type, the choice of positive or negative mode, etc., the ionization method can be determined. Adiponectin can be ionized in positive or negative mode. In some embodiments, adiponectin is ionized by ESI in positive ion mode.
[00111] In mass spectrometry techniques, generally, after sample ionization, the positively or negatively charged ions thus created can be analyzed to determine the mass-to-charge ratio (m / z). Various analyzers for determining m / z include quadrupole analyzers, ion trap analyzers, time-of-flight analyzers, Fourier transform ion cyclotron resonance mass analyzers, and orbitrap analyzers. Some exemplary ion trap methods are described in Bartolucci et al., Rapid Commun. 2000, 14:967-73. Petition 870260109721, dated 10 / 23 / 2026, page 35 / 141 31 / 64
[00112] Ions can be detected using various detection modes. For example, selected ions can be detected, i.e., using a selective ion monitoring (SIM) mode, or alternatively, mass transitions resulting from collision-induced dissociation or loss of neutron can be monitored, for example, multiple reaction monitoring (MRM) or selected reaction monitoring (SRM). In some embodiments, the mass-to-charge ratio is determined using a quadrupole analyzer. In a quadrupole instrument or quadrupole ion trap, ions in an oscillating radiofrequency field experience a force proportional to the DC potential applied between the electrodes, the amplitude of the RF signal, and the mass-to-charge ratio. The voltage and amplitude can be selected so that only ions with a specific mass-to-charge ratio travel the length of the quadrupole, while all other ions are deflected.Thus, quadrupole instruments can act as both a mass filter and a mass detector for the ions injected into the instrument.
[00113] As ions collide with the detector, they produce a pulse of electrons that are converted into a digital signal. The acquired data is relayed to a computer, which plots the counts of collected ions as a function of time. The resulting mass chromatograms are similar to those generated in traditional HPLC-MS methods. The areas under the peaks corresponding to specific ions, or the amplitude of such peaks, can be measured and correlated to the amount of analyte of interest. In certain embodiments, the area under the curves, or the amplitude of the peaks, for fragment ions and / or precursor ions are measured to determine the amount of adiponectin. The relative abundance of a given ion can be converted into an absolute amount of the original analyte using standard calibration curves based on pi. Petition 870260109721, dated 10 / 23 / 2026, page 36 / 141 32 / 64 cos of one or more ions of an internal or external molecular standard.
[00114] It is possible to improve the resolution of MS techniques by employing certain mass spectrometric analyzers through tandem mass spectrometry or MS / MS. In this technique, a precursor ion (also called a parent ion) generated from a molecule of interest can be filtered in an MS instrument, and the precursor ion subsequently fragmented to produce one or more fragment ions (also called daughter ions or product ions) that are then analyzed in a second MS procedure. Through careful selection of the precursor ions, only the ions produced by specific analytes are passed to the fragmentation chamber, where collisions with atoms of an inert gas produce the fragment ions.Since both precursor ions and fragment ions are reproducibly produced under a given set of ionization / fragmentation conditions, the MS / MS technique can provide an extremely powerful analytical tool. For example, the filtration / fragmentation combination can be used to eliminate interfering substances and can be particularly useful in complex samples, such as biological samples. In certain embodiments, a mass spectrometric instrument with multiple quadrupole analyzers (such as a triple quadrupole instrument) is employed to conduct tandem mass spectrometric analysis.
[00115] In certain embodiments using the MS / MS technique, precursor ions are isolated for subsequent fragmentation, and collision-activated dissociation (CAD) is used to generate fragmented ions from the precursor ions for subsequent detection. In CAD, precursor ions gain energy through collisions with an inert gas and subsequently fragment through a process called unimolecular decomposition. Sufficient energy must be deposited. Petition 870260109721, dated 10 / 23 / 2026, page 37 / 141 33 / 64 cited in the precursor ion so that certain bonds within the ion can be broken due to the increase in vibrational energy.
[00116] In some embodiments, adiponectin in a sample is detected and / or quantified using MS / MS as follows. Adiponectin is enriched in a sample by first subjecting it to SPE, then to liquid chromatography, preferably HPLC; the liquid solvent stream from a chromatographic analytical column enters the heated nebulizer interface of an MS / MS analyzer; and the solvent / analyte mixture is converted to vapor in the heated charged tubing of the interface. During these processes, the analyte (i.e., adiponectin) is ionized. The ions, for example, precursor ions, pass through the instrument orifice and enter the first quadrupole. Quadrupoles 1 and 3 (Q1 and Q3) are mass filters, allowing ion selection (i.e., selection of precursor ions and fragments in Q1 and Q3, respectively) based on their mass-to-charge ratio (m / z). Quadrupole 2 (Q2) is the collision cell, where ions are fragmented.The first quadrupole of the mass spectrometer (Q1) selects molecules with the am / z of an adiponectin ion. Precursor ions with the correct am / z can pass to the collision chamber (Q2), while unwanted ions with any other m / z collide with the sides of the quadrupole and are eliminated. Precursor ions entering Q2 collide with neutral gas molecules (such as argon molecules) and fragment. The generated fragment ions are passed to quadrupole 3 (Q3), where they are selected for detection.
[00117] Ionization of adiponectin can result in precursor ions with multiple charges (such as 4+, 5+, 6+ precursor ions, etc.). Ionization conditions, particularly the pH of the buffer used in electrovaporization techniques, significantly influence the identity and quantity of adiponectin precursor ions generated. Methods can utilize acidic or basic conditions; pre Petition 870260109721, dated 10 / 23 / 2026, page 38 / 141 34 / 64 possibly acidic conditions.
[00118] The methods may involve MS / MS performed in positive or negative ion mode; preferably in positive ion mode. In certain embodiments, the electrovaporization buffer is acidic and Q1 selects adiponectin precursor ions with a m / z of about 421.23 ± 0.5. Fragmentation of any of these adiponectin precursor ions generates fragment ions with m / z of about 637.37 ± 0.5, 540.31 ± 0.5 and / or 319.19 ± 0.5. Thus, in embodiments where Q1 selects one or more adiponectin precursor ions selected from the group consisting of ions with m / z of about 421.23 ± 0.5, Q3 may select one or more fragment ions selected from the group of ions with m / z of about 637.37 ± 0.5, 540.31 ± 0.5 and / or 319.19 ± 0.5. In certain embodiments, the relative abundance of a single fragment ion of a single precursor ion may be measured. Alternatively, the relative abundances of two or more fragment ions of a single precursor ion may be measured.In these embodiments, the relative abundances of each fragment ion can be subjected to any known mathematical treatment to quantitatively assess the adiponectin originally present in the sample. In other embodiments, one or more fragment ions of two or more precursor ions can be measured and used as above to qualitatively assess the adiponectin originally present in the sample.
[00119] Alternative modes of operation of a tandem mass spectrometry instrument that can be used in certain modalities include product ion scanning and precursor ion scanning. For a description of these modes of operation, see, for example, E. Michael Thurman et al., Chromatographic-Mass Spectrometric Food Analysis for Trace Determination of Pesticide Residues, Chapter 8 (Amadeo R. Fernandez-Alba, ed., Elsevier 2005) (387). Petition 870260109721, dated 10 / 23 / 2026, page 39 / 141 35 / 64
[00120] In other embodiments, a high-resolution / high-precision mass analyzer can be used for quantitative analysis of adiponectin according to the methods of the present invention. To achieve acceptable precision for quantitative results, the mass spectrometer should be capable of exhibiting a resolving power (FWHM) of 10,000 or more, with an accuracy of about 50 ppm or less for the ions of interest; preferably, the mass spectrometer should exhibit a resolving power (FWHM) of 18,000 or better, with an accuracy of about 5 ppm or less; such as a resolving power (FWHM) of 20,000 or better and an accuracy of about 3 ppm or less; such as a resolving power (FWHM) of 25,000 or better and an accuracy of about 3 ppm or less.Three exemplary analyzers capable of exhibiting the necessary level of performance for adiponectin ions are orbitrap mass analyzers, certain TOF mass analyzers, and Fourier transform ion cyclotron resonance mass analyzers.
[00121] Elements found in active biological molecules, such as carbon, oxygen, and nitrogen, exist naturally in several different isotopic forms. For example, most carbon is present as 12C, but approximately 1% of all natural carbon is present as 13C. Thus, some fraction of natural molecules containing at least one carbon atom will contain at least one 13C atom. The inclusion of natural elemental isotopes in molecules gives rise to multiple molecular isotopic forms. The difference in masses of molecular isotopic forms is at least 1 atomic mass unit (amu). This is because elemental isotopes differ by at least one neutron (mass of a neutron ~ 1 amu). When molecular isotopic forms are ionized to multiple charge states, the mass distinction between isotopic forms can become difficult to discern because detection Petition 870260109721, dated 10 / 23 / 2026, page 40 / 141 36 / 64 by mass spectrometry is based on the mass-to-charge ratio (m / z). For example, two isotopic forms with different masses in 1 μm, both ionized to a 5+ state, will show differences in their m / z of only 0.2. High-resolution / high-precision mass spectrometers are capable of discerning between isotopic forms of ions with multiple charges (such as ions with charges of ±2, ±3, ±4, ±5 or higher).
[00122] Due to the natural occurrence of elemental isotopes, there are typically multiple isotopic forms for each molecular ion (each of which can give rise to a separately detectable spectrometric peak if analyzed with a sufficiently sensitive mass spectrometry instrument). The m / ze ratios, the relative abundances of multiple isotopic forms, collectively constitute an isotopic signature for a molecular ion. In some embodiments, the m / ze ratios, the relative abundances of two or more molecular isotopic forms, can be used to confirm the identity of a molecular ion under investigation. In some embodiments, the mass spectrometric peak of one or more isotopic forms is used to quantify a molecular ion. In some related embodiments, a single mass spectrometric peak of an isotopic form is used to quantify a molecular ion.In other related modalities, a plurality of isotopic peaks is used to quantify a molecular ion. In these later modalities, the plurality of isotopic peaks can be subjected to any appropriate mathematical treatment. Several mathematical treatments are known in the field and include, but are not limited to, summing the area under multiple peaks or averaging the response of multiple peaks.
[00123] In some embodiments, the relative abundance of one or more ions is measured with a high-resolution mass spectrometer. Petition 870260109721, dated 10 / 23 / 2026, page 41 / 141 37 / 64 resolution / high precision to qualitatively assess the amount of adiponectin in the sample. In some modalities, one or more ions measured by high-resolution / high-precision mass spectrometry are multi-charged adiponectin ions.
[00124] The use of high-resolution orbitrap analyzers has been reported for qualitative and quantitative analyses of various analytes. See, for example, U.S. Patent Application Pub. No. 2008 / 0118932 (filed November 9, 2007); Bredehoft, et al., Rapid Commun. Mass Spectrom., 2008, 22:477-485; Le Breton, et al., Rapid Commun. Mass Spectrom., 2008, 22:3130-36; Thevis, et al., Mass Spectrom. Reviews, 2008, 27:35-50; Thomas, et al., J. Mass Spectrom., 2008, 43:908-15; Schenk, et al., BMC Medical Genomics, 2008, 1:41; and Olsen, et al., Nature Methods, 2007, 4:709-12.
[00125] The results of an analyte assay can be related to the amount of analyte in the original sample by several methods known in the art. For example, given that the sampling and analysis parameters are carefully controlled, the relative abundance of a particular ion can be compared to a table that converts this relative abundance into an absolute amount of the original molecule. Alternatively, external standards can be run with the samples and a standard curve constructed based on the ions generated from these standards. Using this standard curve, the relative abundance of a particular ion can be converted into an absolute amount of the original molecule. In certain preferred embodiments, an internal standard is used to generate a standard curve for calculating the amount of adiponectin. The methods of generating and using these standard curves are well known in the art, and one skilled in the art is able to select an appropriate internal standard.For example, in preferred embodiments, one or more isotopically labeled forms of adiponectin may be used as a precursor. Petition 870260109721, dated 10 / 23 / 2026, page 42 / 141 38 / 64 internal ions. Several other methods for relating the quantity of an ion to the quantity of the original molecule will be well known to those skilled in the art.
[00126] As used herein, an isotopic label produces a mass shift in the labeled molecule relative to the unlabeled molecule when analyzed by mass spectrometry techniques. Examples of suitable labels include deuterium (2H), 13C, and 15N. One or more isotopic labels may be incorporated at one or more positions in the molecule, and one or more types of isotopic labels may be used in the same isotopically labeled molecule.
[00127] In other modalities, adiponectin may be subjected to chemical treatment prior to mass spectrometric analysis. For example, adiponectin may be treated with TCEP (tris(2-carboxyethyl)phosphine).
[00128] Adiponectin can then be subjected to one or more of the purification steps described above. In preferred embodiments, adiponectin is subjected to HPLC purification prior to mass spectrometric analysis.
[00129] Once purified, adiponectin is then subjected to an ionization source.
[00130] In preferred modalities, adiponectin is ionized by ESI in positive mode.
[00131] One or more steps of any of the methods described above may be performed using automated machines. In certain embodiments, one or more purification steps are performed online and, more preferably, all purification and mass spectrometry steps may be performed online.
[00132] The following examples serve to illustrate the invention. These examples are not intended, in any way, to limit the scope of Petition 870260109721, dated 10 / 23 / 2026, p. 43 / 141 39 / 64 methods. EXAMPLES
[00133] Example 1: Adiponectin LC / MS. General methods for quantifying adiponectin in a human serum sample via LC / MS. Calibration standards, quality controls (QCs), and internal standards (IS) were made by reconstituting recombinant human adiponectin or peptides in MilliQ water and then diluting in extracted serum. The concentrations of the calibrator raw material and IS solutions were established using amino acid (AAA) analysis by an independent laboratory. Calibration standards, QCs, and patient samples were thermally denatured and digested with trypsin TPCK (N-tosyl-L-phenylalanine chloromethyl ketone) after adding IS to sodium deoxycholate (DOC) solution. Digestion was stopped, and the DOC was precipitated with formic acid. After centrifugation, the sample supernatants were transferred to a 96-well plate for injection into an Agilent StreamSelect LC system coupled to an Agilent 6495C QqQ MS.Adiponectin was resolved chromatographically using 2.6 pm Kinetex C18 columns (Phenomenex) and gradients of water and acetonitrile (both containing 0.1% formic acid). The analyte and SI were monitored by electrovaporization ionization in positive ion mode with multiple reaction monitoring (MRM). The following ions were used in the analysis of adiponectin in this method. Table 2 Compound Adiponectin Internal Standard Ions (m / z) 421.23 ± 0.5 416.22 ± 0.5 314.18 ± 0.5 319.19 ± 0.5 627.36 ± 0.5 637.37 ± 0.5 530.30 ± 0.5 540.31 ± 0.5
[00134] Example 2: Precision. A total of 98 samples were compared in 5 runs performed on 5 different days between a Petition 870260109721, dated 10 / 23 / 2026, page 44 / 141 40 / 64 all validated ELISA (enzyme-linked immunosorbent assay) and the Starscream MS (LC-MS / MS) under validation. Regression was assessed for accuracy at the highest (37 pg / mL) and lowest (2 pg / mL) extremes of the population reference range.
[00135] The comparison between the validated ELISA method and the LC / EM method produced a slope of 1.008 with an intercept of -0.167 (Table 3; Figure 1). The cut-off points of 2, 15, and 37 pg / mL meet the acceptance criteria with a mean bias < TEa / 4. The bias for the sample comparison between the validated ELISA method and the MS Starscream method is acceptable (within TEa / 4). Table 3. Comparison between the validated ELISA method and the LC / MS method. Tea (Total Error Allowed): 30.0% or 1.50 pg / mL Sample # ELISA (X) Mass Spectrometry (Y) Difference, YX Difference, (YX) / X (%) 1 21.05 23.52 2.47 12% 2 8.61 8.75 0.15 2% 3 27.16 30.39 3.23 12% 4 28.08 32.66 4.58 16% 5 24.98 23.72 -1.26 -5% 6 16.55 21.26 4.71 28% 7 13.43 17.56 4.13 31% 8 12.03 10.91 -1.12 -9% 9 21.43 16.99 -4.44 -21% 10 39.81 32.57 -7.24 -18% 11 18.46 21.62 3.16 17% 12 5.98 6.31 0.33 6% 13 22.42 36.56 14.14 63% 14 3.99 5.23 1.24 31% 15 30.36 24.85 -5.51 -18% 16 10.81 13.29 2.48 23% 17 13.46 13.33 -0.13 -1% Petition 870260109721, dated 10 / 23 / 2026, page 45 / 141 41 / 64 Sample # ELISA (X) Mass Spectrometry (Y) Difference, YX Difference, (YX) / X (%) 18 23.60 20.28 -3.32 -14% 19 27.96 24.13 -3.83 -14% 20 17.73 17.16 -0.57 -3% 21 9.62 12.90 3.28 34% 22 25.80 26.76 0.96 4% 23 11.83 7.46 -4.37 -37% 24 17.81 22.25 4.44 25% 25 11.51 8.42 -3.09 -27% 26 17.30 12.81 -4.49 -26% 27 15.41 11.54 -3.87 -25% 28 13.90 20.13 6.23 45% 29 28.66 28.91 0.25 1% 30 8.93 11.35 2.42 27% 31 19.89 35.33 15.45 78% 32 14.63 10.80 -3.83 -26% 33 31.57 32.98 1.41 4% 34 10.86 10.42 -0.44 -4% 35 14.60 8.85 -5.75 -39% 36 13.09 14.08 0.99 8% 37 12.23 7.47 -4.76 -39% 38 23.03 19.03 -4.00 -17% 39 8.23 16.37 8.14 99% 40 22.63 18.95 -3.68 -16% 41 3.56 5.76 2.20 62% 42 17.99 21.19 3.20 18% 43 18.36 25.44 7.08 39% 44 28.00 31.62 3.62 13% 45 33.72 24.10 -9.62 -29% 46 26.43 22.47 -3.96 -15% 47 31.40 23.05 -8.35 -27% 48 16.02 15.38 -0.64 -4% Petition 870260109721, dated 10 / 23 / 2026, page 46 / 141 42 / 64 Sample # ELISA (X) Mass Spectrometry (Y) Difference, YX Difference, (YX) / X (%) 49 7.22 3.22 -4.00 -55% 50 22.66 18.61 -4.05 -18% 51 23.53 31.12 7.59 32% 52 40.00 27.59 -12.41 -31% 53 40.00 34.05 -5.95 -15% 54 40.00 29.65 -10.35 -26% 55 8.60 8.80 0.20 2% 56 8.60 10.20 1.60 19% 57 8.60 8.47 -0.13 -2% 58 7.70 10.10 2.40 31% 59 6.40 5.00 -1.40 -22% 60 12.65 9.27 -3.38 -27% 61 14.38 12.31 -2.07 -14% 62 10.55 7.98 -2.57 -24% 63 23.53 21.47 -2.06 -9% 64 24.41 30.40 5.99 25% 65 20.65 18.56 -2.09 -10% 66 15.72 20.24 4.52 29% 67 35.40 35.83 0.43 1% 68 5.20 4.67 -0.53 -10% 69 35.40 40.69 5.29 15% 70 5.20 4.79 -0.41 -8% 71 17.10 18.67 1.57 9% 72 17.10 18.51 1.41 8% 73 17.10 16.52 -0.58 -3% 74 17.10 20.25 3.15 18% 75 17.10 18.47 1.37 8% 76 40.00 39.31 -0.69 -2% 77 40.00 40.49 0.49 1% 78 40.00 39.58 -0.42 -1% 79 40.00 37.98 -2.02 -5% Petition 870260109721, dated 10 / 23 / 2026, page 47 / 141 43 / 64 Sample # ELISA (X) Mass Spectrometry (Y) Difference, YX Difference, (YX) / X (%) 80 40.00 40.23 0.23 1% 81 1.56 1.68 0.12 8% 82 3.13 2.45 -0.68 -22% 83 6.25 6.26 0.01 0% 84 12.50 9.83 -2.67 -21% 85 25.00 29.42 4.42 18% 86* 50.00 50.80 0.80 2% 87 17.10 18.97 1.87 11% 88 17.10 17.62 0.52 3% 89 17.10 18.74 1.64 10% 90 17.10 17.44 0.34 2% 91 17.10 17.01 -0.09 -1% 92 17.10 17.12 0.02 0% 93 8.60 8.97 0.37 4% 94 8.60 8.96 0.36 4% 95 8.60 8.75 0.15 2% 96 8.60 9.09 0.49 6% 97 8.60 9.51 0.91 11% 98 8.60 9.16 0.56 7% * In Sample 86, a value above the highest calibration standard (above the analytical measurement range) was recovered.
[00136] Example 3: Inter-Day Precision. QC pools containing high, medium, and low concentrations of recombinant human adiponectin (QCH, QCM, QCL) were prepared in bulk and stored as single-use aliquots at -80 °C. For intra-assay precision, 20 replicates of each level were prepared and analyzed on the same day and in the same batch. For inter-assay precision, 5 replicates of each level were evaluated in 20 separate runs.
[00137] The material with low CQ produced an Overall Average of 4.01 pg / mL with a mean standard deviation (SD) within the run of Petition 870260109721, dated 10 / 23 / 2026, pp. 48 / 141 44 / 64 0.38 pg / mL (CV within the run = 9.40%) and a total SD of 0.40 pg / mL (total CV = 9.94%) for an Overall Sigma = 3.76. Two samples highlighted in yellow and bold were removed from the data calculations as they were considered outliers.
[00138] The QC medium material produced an overall average of 13.28 pg / mL with an within-run average standard deviation of 0.83 pg / mL (within-run CV = 6.28%) and a total standard deviation of 0.92 pg / mL (total CV = 6.90%) for an Overall Sigma = 4.35.
[00139] The QC High material produced an overall average of 22.30 pg / mL with an within-run average standard deviation of 1.29 pg / mL (within-run CV = 5.78%) and a total standard deviation of 1.43 pg / mL (total CV = 6.40%) for an Overall Sigma = 4.69.
[00140] All three QC levels meet the TEa / 3 total precision acceptance criteria (Table 4; Figure 2). Table 4. Accuracy between days and quality control levels QC Low Rep 1 Rep 2 Rep 3 Rep 4 Rep 5 Average Account w / i SD execution 1 4.08 4.21 3.89 4.15 3.63 5 3.99 0.24 2 3.78 4.17 3.56 2.34 4.13 4 3.91 0.29 3 3.70 4.28 4.30 4.21 4.53 5 4.20 0.31 4 4.01 4.95 3.93 4.26 4.73 5 4.38 0.45 5 4.13 5.94 4.40 3.87 4.13 4 4.13 0.22 6 3.49 4.13 3.53 3.75 4.15 5 3.81 0.32 7 3.84 3.22 3.71 3.63 3.98 5 3.68 0.29 8 3.27 4.27 4.04 4.09 4.01 5 3.94 0.39 9 4.38 3.37 4.15 3.38 3.11 5 3.68 0.55 10 4.28 3.89 4.13 4.14 4.34 5 4.16 0.17 11 3.90 4.24 3.71 3.98 3.92 5 3.95 0.19 12 3.83 3.92 3.95 3.87 3.53 5 3.82 0.17 13 3.88 4.03 4.25 4.47 4.26 5 4.18 0.23 14 4.50 3.36 4.62 4.55 4.35 5 4.28 0.52 15 4.38 4.57 3.46 3.62 3.89 5 3.98 0.48 Petition 870260109721, dated 10 / 23 / 2026, pp. 49 / 141 45 / 64 QC Low Rep 1 Rep 2 Rep 3 Rep 4 Rep 5 Average Account w / i SD execution 16 4.57 3.36 4.20 3.58 4.30 5 4.00 0.51 17 4.11 4.35 3.75 3.55 4.72 5 4.10 0.47 18 3.73 3.58 4.21 3.75 3.65 5 3.78 0.25 19 4.38 4.55 4.29 4.30 3.57 5 4.22 0.38 20 3.47 4.41 5.09 4.72 4.29 5 4.40 0.60 21 13.49 13.40 13.85 13.18 14.93 5 13.77 0.69 22 14.39 13.77 12.28 13.97 13.37 5 13.56 0.80 23 13.73 13.18 12.33 13.09 13.63 5 13.19 0.56 24 13.98 13.88 15.24 15.37 14.31 5 14.56 0.70 25 12.14 10.91 12.20 14.14 12.31 5 12.34 1.16 26 13.27 13.29 14.18 13.79 13.32 5 13.57 0.40 27 12.76 13.00 12.58 13.89 13.77 5 13.20 0.60 28 14.28 13.29 13.92 13.10 14.06 5 13.73 0.51 29 11.92 12.73 12.93 13.17 10.55 5 12.26 1.07 30 12.34 13.57 13.84 13.36 13.96 5 13.41 0.64 31 12.00 12.38 13.43 14.57 14.69 5 13.41 1.23 32 11.62 12.92 12.64 12.57 12.61 5 12.47 0.50 33 14.33 13.07 13.39 13.88 13.14 5 13.56 0.53 34 13.08 12.67 12.26 13.36 12.41 5 12.76 0.46 35 15.11 13.27 12.91 13.13 14.50 5 13.78 0.97 36 12.81 13.73 11.90 14.31 13.12 5 13.17 0.92 37 12.69 11.96 12.90 14.71 14.53 5 13.36 1.21 38 13.46 13.51 13.44 12.60 13.27 5 13.26 0.38 39 13.74 13.85 12.80 12.03 13.23 5 13.13 0.74 40 12.89 10.98 13.83 13.34 14.98 5 13.20 1.47 41 22.88 22.06 23.75 22.28 21.18 5 22.43 0.96 42 21.44 23.26 22.95 21.92 22.03 5 22.32 0.76 43 25.51 22.35 22.61 22.61 20.06 5 22.63 1.94 44 20.23 21.93 20.96 20.07 20.07 5 20.65 0.80 45 23.78 24.62 22.78 20.74 21.72 5 22.73 1.55 46 22.42 22.96 22.81 23.24 24.18 5 23.12 0.66 Petition 870260109721, dated 10 / 23 / 2026, p. 50 / 141 46 / 64 QC Low Rep 1 Rep 2 Rep 3 Rep 4 Rep 5 Average Account w / i SD execution 47 22.71 22.99 22.77 20.92 23.99 5 22.68 1.11 48 21.43 23.00 23.10 21.14 23.18 5 22.37 1.00 49 21.98 22.23 22.96 22.20 23.03 5 22.48 0.48 50 22.35 23.08 21.53 20.23 22.27 5 21.89 1.08 51 22.88 21.74 20.38 19.33 20.72 5 21.01 1.35 52 23.07 23.65 24.12 22.15 22.43 5 23.08 0.82 53 22.28 23.80 23.29 23.50 24.08 5 23.39 0.69 54 22.40 22.84 24.65 23.66 21.13 5 22.94 1.32 55 20.70 20.19 24.46 22.53 24.80 5 22.54 2.10 56 21.01 23.76 21.32 20.34 19.23 5 21.13 1.67 57 21.35 25.77 21.79 19.08 21.73 5 21.94 2.41 58 22.84 23.50 22.41 22.14 22.18 5 22.61 0.57 59 22.95 24.60 21.41 24.28 24.19 5 23.49 1.32 60 20.04 19.59 21.41 21.97 20.13 5 20.63 1.01 Table 5. Summary Summary Level 1 Level 2 Level 3 Count 98 100 100 Large average 4.01 13.28 22.30 SD of execution within the average 0.38 0.83 1.29 CV of execution within the average 9.40% 6.28% 5.78% Total SD 0.40 0.92 1.43 Total CV 9.94% 6.90% 6.40% Global Sigma 3.76 4.35 4.69 Precision >= 3.0 sigma? YES YES YES
[00141] Example 4: Intraday accuracy
[00142] Level 1 (low QC) produced an average of 4.53 μg / mL. The SD within the run was 0.37 pg / mL (CV within the run = 8.13%).
[00143] Level 2 (average CQ) produced an average of 14.02 μg / mL. The SD within the run was 1.03 pg / mL (CV within the run = Petition 870260109721, dated 10 / 23 / 2026, page 51 / 141 47 / 64 7.37%).
[00144] Level 3 (high QC) produced an average of 24.08 pg / mL. The SD within the run was 1.56 pg / mL (CV within the run = 6.48%).
[00145] All three QC levels meet the TEa / 3 total precision acceptance criteria (Table 6). Table 6. Intraday accuracy and quality control levels Level 1 Rep 1 Level 2 Rep 1 Level 3 Rep 1 1 4.20 1 13.57 1 24.76 2 4.41 2 15.29 2 24.26 3 4.68 3 13.88 3 24.58 4 4.43 4 13.14 4 26.02 5 4.56 5 13.21 5 25.92 6 4.52 6 12.67 6 27.49 7 4.69 7 14.76 7 24.19 8 5.08 8 13.06 8 25.30 9 4.20 9 15.31 9 24.51 10 3.88 10 14.26 10 25.61 11 5.20 11 15.91 11 22.77 12 5.20 12 12.99 12 23.31 13 4.77 13 15.09 13 23.47 14 4.26 14 12.59 14 22.28 15 4.03 15 14.33 15 23.80 16 4.25 16 13.86 16 23.29 17 4.47 17 14.33 17 23.50 18 4.32 18 13.07 18 24.08 19 4.46 19 13.39 19 21.42 20 4.91 20 15.66 20 21.13 Level 1 Level 2 Level 3 N 20 N 20 N 20 X 4.53 X 14.02 X 24.08 Petition 870260109721, dated 10 / 23 / 2026, p. 52 / 141 48 / 64 SD within run 0.37 CV within run 8.13% Sigma 4.08 Prec >3.0 YES SD within run 1.03 CV within run 7.37% Sigma 4.07 Prec >3.0 YES SD within run 1.56 CV within run 6.48% Sigma 4.63 Prec >3.0 YES
[00146] Example 5: Analytical Measurement Range (AMR). The AMR verification was performed using two different batches of recombinant protein with target concentrations assigned by third-party amino acid analysis and serially diluted throughout the AMR. The samples with the lowest and highest values had target values within 1.5 TEa of the lower and upper limits of the AMR, respectively. All samples were measured in triplicate replicates.
[00147] The acceptance criterion for adiponectin is that the average of three replicate measurements at each level is recovered within TEa / 4 (7.5% or 0.375 pg / mL), from 1.50 pg / mL to 50.00 pg / mL.
[00148] The acceptance criteria were met across the entire AMR from 1.50 pg / mL to 50.00 pg / mL (Table 7; Figure 3). Table 7. AMR and acceptance criteria TEa: 30% or 1.50 pg / mL Target Sample Rep1 Rep2 Rep3 Average TEa / 4 min max Within range Index 1 1.56 1.68 1.5 1.3 1.52 0.38 1.19 1.94 YES -12% 2 3.13 3.11 3.0 3.4 3.16 0.38 2.75 3.50 YES 8% 3 6.25 6.45 6.4 6.6 6.50 0.47 5.78 6.72 YES 53% 4 12.5 10.9 12.1 12.7 11.89 0.94 11.56 13.44 YES -65% 5 25.0 26.3 25.6 24.6 25.48 1.88 23.13 26.88 YES 26% 6 50.0 50.8 53.7 49.7 51.39 3.75 46.25 53.75 YES 37% Petition 870260109721, dated 10 / 23 / 2026, page 53 / 141 49 / 64 Table 8. Analysis y = 1.03x - 0.238 LL of AMR in parentheses YES UL of AMR in parentheses YES LL recovered YES UL recovered YES Recovered from midpoint YES AMR validated YES
[00149] Example 6: Carryover. Samples were injected three separate times using the following sequence: low concentration, low concentration, high concentration, high concentration, low concentration, low concentration, low concentration (the low concentration material was QC Low and the high concentration material was calibrator 1).
[00150] The acceptance criterion is that the carryover from the high concentration sample to a low concentration sample does not exceed TEa / 4 for each reported parameter.
[00151] Carryover and pre-carryover did not exceed TEa / 4 for adiponectin, thus passing the acceptance criteria (Table 9, Figure 4). Table 9. Transition. LC3 TEa: 30.0% or 1.50 pg / mL Cup # Type Execution #1 Execution #2 Execution #3 1 Low 3.730 3.190 3.340 2 Low 3.680 3.180 3.220 3 High 50.240 48.850 51.310 4 High 53.470 51.340 49.790 5 Low 3.990 3.850 4.290 6 Low 3.290 1.690 3.280 7 Low 4.320 3.900 4.410 Petition 870260109721, dated 10 / 23 / 2026, page 54 / 141 50 / 64 Table 10 Medium Low 4.025 3.545 3.875 Medium High 51.9 50.1 50.6 Transport in cup 5 -0.035 0.305 0.415 Transport in cup 6 -0.735 -1.855 -0.595 Pre-transport in cup 2 -0.345 -0.365 -0.655 Table 11 Average TEa / 4 Transfer ? Transport in cup 5 0.228 0.375 No transfer Transport in cup 6 -1.062 0.375 No transfer Pre-transport in cup 2 -0.455 0.375 No transfer LC4 TEa 30% or 1.50 pg / mL Table 12 Cup # Type Execution No. 1 Execution No. 2 Execution No. 3 1 Low 4.300 3.670 4.420 2 Low 3.310 3.010 2.720 3 High 62.760 59.040 66.280 4 High 50.400 49.290 48.820 5 Low 3.490 4.370 3.430 6 Low 4.230 1.900 3.390 7 Low 3.460 3.510 3.140 Table 13 Medium Low 3.880 3.590 3.780 Medium High 56.6 54.2 57.6 Transport in cup 5 -0.390 0.780 -0.350 Transport in cup 6 0.350 -1.690 -0.390 Pre-transport in cup 2 -0.570 -0.580 -1.060 Petition 870260109721, dated 10 / 23 / 2026, page 55 / 141 51 / 64 Table 14 Average TEa / 4 Transfer Transport in cup 5 0.013 0.375 No transfer Transport in cup 6 -0.577 0.375 No transfer Pre-transport in cup 2 -0.737 0.375 No transfer
[00152] Example 7: Analytical Sensitivity. The limit of quantification (LOQ), limit of blank (LOB), and limit of detection (LOD) were verified by analyzing 25 replicate matrix blanks and 25 replicates at the lower limit of the AMR. Samples for the lower limit test were created by adding recombinant human adiponectin extracted from serum to obtain the concentrations of each parameter.
[00153] The acceptance criterion is low pool concentration < (LL AMR + 1.5*TEa) and low pool imprecision is SD < TEa / 3.
[00154] The LOB was calculated at 0.419 pg / mL, the LOD at 0.740 pg / mL, and the LOQ at 0.831 pg / mL. Each of the pools with low values presented an SD < TEa / 3 and passed the acceptance criteria. (Table 15, Figure 5). Table 15. Analytical Sensitivity TEa 30% or 1.50 pg / mL Execution # Result # Group A Pool B Pool C zero calories 1 1 0.580 0.910 1.750 0.000 2 0.480 0.960 2.190 0.000 3 0.660 1.220 1.680 0.000 4 1.200 0.970 2.850 0.420 5 0.790 1.290 2.880 0.150 2 1 1.670 2.630 1.510 0.000 2 0.920 0.910 2.120 0.000 3 0.990 1.740 2.010 0.000 4 1.010 1.560 2,320 0,230 5 0,640 0,900 2,180 0,210 3 1 0,540 0,990 2,310 0,000 2 0,820 0,970 1,870 0,000 3 0,960 1,490 1,690 0,000 Petition 870260109721, dated 10 / 23 / 2026, page 56 / 141 52 / 64 Execution # Result # Group A Pool B Pool C zero calories 4 0.820 1.540 2.150 0.000 5 1.130 1.440 1.800 0.210 4 1 0.850 0.860 2.270 0.000 2 1.280 1.080 2.390 0.000 3 0.860 1.400 2.000 0.090 4 0.830 1.890 1.450 0.560 5 0.660 1.260 2.060 0.000 5 1 0.390 1.570 1.640 0.410 2 0.580 2.290 2,110 0,010 3 0,890 2,100 1,850 0,000 4 0,680 1,510 1,660 0,170 5 0,540 1,690 2,570 0,000 Table 16 Count 25 25 25 25 Average 0.831 1.407 2.052 0.098 SD 0.285 0.468 0.378 0.160 TEa / 3 0.500 0.500 0.500 SD < TEa / 3? YES YES YES Is the average >= LOD? YES YES YES Limit of White Space (LOB) 0.419 Limit of Detection (LOD) 0.740 Limit of Quantification (LOQ) 0.831
[00155] Example 8: Sample stability. Stability was assessed by measuring adiponectin in a minimum of 7 freshly collected single-donor serum samples over time under ambient (18 to 25 °C), refrigerated (2 to 8 °C), frozen (20 °C) and ultra-frozen (-70 °C) conditions.
[00156] The acceptance criterion is that the average value recovered from the evaluated samples does not deviate from Day 0 by more than TEa / 3 (the greater of 10% or 0.5 pg / mL). Room temperature (18 to 25°C)
[00157] The samples were analyzed at 0, 24, 48 and 96 hours.
[00158] The average concentration remained within TEa / 3 of the concentration Petition 870260109721, dated 10 / 23 / 2026, p. 57 / 141 53 / 64 average concentration measured at t = 0 for all time points evaluated. (Table 17; Figure 6). Adiponectin is stable for up to 96 hours at room temperature. Table 17. Sample stability (environment) TEa: 30% or 1.50 pg / mL Ambient Temperature (18 to 25 °C) Hours Sample # 0 24 48 96 1 11.26 9.37 10.18 8.95 2 24.44 17.52 17.87 15.61 3 8.73 7.16 6.94 5.80 4 17.38 28.71 18.69 15.19 5 10.70 13.81 12.52 12.47 6 7.82 9.40 6.74 8.13 7 8.54 8.65 9.45 9.90 9 6.52 9.24 6.62 5.34 10 25.66 24.81 24.08 30.18 Average 13.45 14.30 12.57 12.40 Table 18 Target +TEa / 3 14.80 Daily Goal 0 13.45 Target -TEa / 3 12.11 Refrigerated (2 to 8°C)
[00159] The samples were analyzed at 0, 2, 4, 6 and 20 days.
[00160] The average concentration remained within TEa / 3 of the average concentration measured at t = 0 for all time points evaluated (Table 19; Figure 7). Adiponectin is stable for up to 20 days at refrigerated temperature. Table 19. Sample stability (refrigerated) TEa: 30% or 1.50 pg / mL Refrigerated (2 to 8 C°) Days Sample # 0 2 4 6 20 1 11.26 10.17 12.12 10.13 10.96 2 24.44 15.09 17.62 16.47 22.27 3 8.73 5.82 8.09 7.47 10.23 Petition 870260109721, dated 10 / 23 / 2026, page 58 / 141 54 / 64 Refrigerated (2 to 8 C°) Days Sample # 0 2 4 6 20 4 17.38 14.46 18.04 17.20 15.25 5 10.70 14.95 13.43 13.55 17.27 6 7.82 5.73 8.29 7.55 9.85 7 8.54 16.77 8.53 8.99 12.84 8 39.77 40.91 40.86 35.21 39.90 9 6.52 7.03 7.30 7.06 5.73 10 25.66 34.27 24.66 27.45 27.19 Average 16.08 16.52 15.89 15.11 17.15 Table 20 Target +TEa / 3 17.69 Daily Goal 0 16.08 Target -TEa / 3 14.47 Frozen (-20°C)
[00161] The samples were analyzed at 0, 6, 13, 20 and 27 days.
[00162] The average concentration remained within TEa / 3 of the average concentration measured at t = 0 for all time points up to 20 days (Table 21; Figure 8). Adiponectin is stable for up to 20 days at frozen temperature. Table 21. Sample stability (frozen) TEa: 30% or 1.50 pg / mL Frozen (-20°C) Days Sample # 0 6 13 20 27 1 11.26 10.59 9.96 9.75 9.09 2 24.44 20.00 15.13 19.43 12.61 3 8.73 5.35 7.94 7.66 5.42 4 17.38 16.40 20.75 18.33 15.66 5 10.70 14.35 14.46 11.40 12.23 6 7.82 4.94 6.41 6.14 5.65 7 8.54 9.45 7.10 9.49 7.13 8 39.77 34.56 43.77 37.89 34.92 9 6.52 7.18 4.46 4.43 3.99 10 25.66 23.27 29.47 24.83 23.12 Average 16.08 14.61 15.95 14.94 12.98 Petition 870260109721, dated 10 / 23 / 2026, p. 59 / 141 55 / 64 Table 22 Target +TEa / 3 17.69 Daily Goal 0 16.08 Target -TEa / 3 14.47 Ultra-frozen (<-70°C)
[00163] The samples were analyzed at 0 and 27 days.
[00164] The average concentration remained within TEa / 3 of the average concentration measured at t = 0 for all time points evaluated (Table 23; Figure 9). Adiponectin is stable for up to 27 days at deep freeze temperature. Table 23. Sample stability (frozen) TEa: 30% or 1.50 pg / mL Ultra-frozen (-70°C) Days Sample # 0 27 1 11.26 12.92 2 24.44 18.04 3 8.73 7.14 4 17.38 14.91 5 10.70 12.95 6 7.82 6.34 7 8.54 9.11 8 39.77 40.19 9 6.52 5.94 10 25.66 26.07 Average 16.08 15.36 Table 24 Target +TEa / 3 17.69 Daily Goal 0 16.08 Target -TEa / 3 14.47 Freeze / thaw stability
[00165] The samples were frozen and thawed 0, 1, 2, 3, 4 and 5 times. Petition 870260109721, dated 10 / 23 / 2026, page 60 / 141 56 / 64
[00166] The average concentration remained within TEa / 3 of the average concentration measured at t = 0 for all freeze / thaw cycles evaluated (Table 25; Figure 10). Adiponectin is stable for up to 5 freeze / thaw cycles. Table 25. Sample stability (freeze / thaw) TEa: 30% or 1.50 pg / mL Original Freeze Thaw Sample 0 1 2 3 4 5 1 12.96 12.84 12.23 12.69 13.04 13.66 2 7.12 8.76 8.1 5.02 6.77 6.92 3 11.76 12.52 12.68 15.93 12.98 13.79 4 6.35 7.08 8.92 6.98 7.41 5.02 5 1.54 0.8 1.48 1.07 0.83 1.7 6 28.5 26.71 27.84 31.56 27.21 25.9 7 1.11 1.03 1.15 1.42 1.32 1.43 8 3.35 3.4 3.19 2.37 2.76 2.29 9 1.13 1.11 0.64 1.54 1.15 0.95 10 25.36 28.42 24.98 26.89 34.03 28.05 Average 9.92 10.27 10.12 10.55 10.75 9.97 Difference 0.35 0.20 0.63 0.83 0.05 TEa / 3 0.99 0.99 0.99 0.99 0.99 Diff <= C,á / 3 YES YES YES YES YES Autosampler stability
[00167] 47 samples were processed and analyzed on days 0 and 6 to evaluate the stability of samples prepared in the instrument's autosampler. Data supporting this study are presented in Table 26 and Figure 11. All reported parameters remained within acceptance criteria throughout the study. Petition 870260109721, dated 10 / 23 / 2026, page 61 / 141 57 / 64 Table 26. Autosampler stability TEa: 30% or 1.50 μg / mL Sample # Sample Type Day 0 (X) Day 6 (E) Difference, Y - X Difference, (YX) / X % AMR* 1 Serum 0.20 0.55 0.35 175% L 2 Serum 0.64 1.29 0.65 102% L 3 Serum 1.17 0.96 -0.21 -18% L 4 Serum 4.02 3.84 -0.18 -4% 5 Serum 7.91 6.25 -1.66 -21% 6 Serum 13.97 10.38 -3.59 -26% 7 Serum 31.16 30.33 -0.83 -3% 8 Serum 55.03 53.23 -1.80 -3% 9 Serum 24.65 22.74 -1.91 -8% 10 Serum 22.40 23.76 1.36 6% 11 Serum 22.84 20.37 -2.47 -11% 12 Serum 20.25 19.35 -0.90 -4% 13 Serum 23.66 24.06 0.40 2% 14 Serum 21.13 23.78 2.65 13% 15 Serum 18.46 17.46 -1.00 -5% 16 Serum 13.08 11.77 -1.31 -10% 17 Serum 12.67 12.34 -0.33 -3% 18 Serum 12.26 12.42 0.16 1% 19 Serum 10.11 10.32 0.21 2% 20 Serum 13.36 11.65 -1.71 -13% 21 Serum 12.41 10.62 -1.79 -14% 22 Serum 12.02 12.41 0.39 3% 23 Serum 4.50 4.17 -0.33 -7% 24 Serum 3.36 3.24 -0.12 -4% 25 Serum 5.30 8.10 2.80 53% 26 Serum 2.80 3.80 1.00 36% 27 Serum 4.62 4.92 0.30 6% 28 Serum 4.55 6.08 1.53 34% Petition 870260109721, dated 10 / 23 / 2026, page 62 / 141 58 / 64 Sample # Sample Type Day 0 (X) Day 6 (E) Difference, Y - X Difference, (YX) / X % AMR* 29 Serum 4.35 5.82 1.47 34% 30 Serum 14.33 15.80 1.47 10% 31 Serum 10.10 8.62 -1.48 -15% 32 Serum 5.00 3.74 -1.26 -25% 33 Serum 9.27 10.21 0.94 10% 34 Serum 17.77 13.71 -4.06 -23% 35 Serum 12.31 12.48 0.17 1% 36 Serum 7.98 9.90 1.92 24% 37 Serum 21.47 21.94 0.47 2% 38 Serum 30.40 28.90 -1.50 -5% 39 Serum 18.56 17.73 -0.83 -4% 40 Serum 20.24 21.45 1.21 6% 41 Serum 10.05 11.23 1.18 12% 42 Serum 35.83 39.71 3.88 11% 43 Serum 4.67 5.94 1.27 27% 44 Serum 1.51 1.96 0.45 30% 45 Serum 40.69 47.71 7.02 17% 46 Serum 4.79 6.03 1.24 26% 47 Serum 1.76 1.56 -0.20 -11% *L: a value below the lowest calibration standard (below the analytical measurement range) was recovered; H: a value above the highest calibration standard (above the analytical measurement range) was recovered.
[00168] Processed samples stored in the autosampler for this assay are stable for 6 days.
[00169] Example 9: Analytical Specificity - Interfering Substances. The acceptance criterion for studies of interfering substances is that the average of the sample results does not deviate from the unaltered measurement by more than TEa / 3. Petition 870260109721, dated 10 / 23 / 2026, page 63 / 141 59 / 64 Hemolysis
[00170] Pools of serum from individual donors were enriched with red blood cell hemolysate at concentrations of 0, 10, 40, 100, 200, and 500 mg / dL and quadrupled. Samples were analyzed at each level, and the results are presented in Tables 27 and Figures 12. All reported parameters remained within acceptance criteria, except for the highest tested concentration of interferent. Samples with macroscopic hemolysis are not acceptable for testing. Table 27. Hemolysis TEa: 30% or 1.50 pg / mL Hemolysis mg / dL Sample 0 10 40 100 200 500 1 29.24 32.25 32.34 34.38 33.30 34.91 2 2.77 2.67 3.14 3.39 3.69 3.87 3 32.25 31.29 32.37 32.66 30.55 35.79 1 24.99 32.12 29.91 35.73 31.21 32.70 2 2.99 3.26 3.31 3.08 3.28 4.34 3 30.71 29.85 29.86 29.76 31.12 29.93 1 30.97 34.05 29.17 35.27 29.65 31.83 2 3.79 3.09 3.99 2.84 4.22 4.15 3 29.45 29.80 30.11 29.47 28.53 33.25 1 27.60 30.66 32.43 31.88 30.53 33.68 2 3.03 3.03 2.85 3.65 3.78 5.30 3 31.01 30.58 29.03 30.97 32.80 30.64 Average 20.73 21.89 21.54 22.76 21.89 23.37 X+Tea / 3 22.8 22.8 22.8 22.8 22.8 22.8 Jaundice (Bilirubin)
[00171] Pools of serum from individual donors were enriched with bilirubin to concentrations of 0, 0.2, 2, and 5 mg / dL and quadrupled. Samples were analyzed at each level and the results Petition 870260109721, dated 10 / 23 / 2026, page 64 / 141 60 / 64 are presented in Table 28 and Figure 13. All reported parameters remained within the acceptance criteria up to the highest tested concentration of interferent. Table 28. Bilirubin TEa: 30% or 1.50 pg / mL Bilirubin mg / dL Sample 0 0.2 2 5 1 38.30 36.11 34.25 39.90 2 3.89 3.45 4.05 3.92 3 34.24 32.69 35.05 35.66 1 39.85 35.00 36.28 37.86 2 3.80 2.87 4.32 8.75 3 34.80 27.73 29.32 35.24 1 31.39 35.22 38.95 37.87 2 3.44 2.29 3.32 5.54 3 33.25 24.96 31.46 32.18 1 36.79 36.18 56.66 34.49 2 3.92 3.63 3.60 2.81 3 30.17 27.93 33.93 31.72 Average 24.49 22.34 23.14 25.50 X +Tea / 3 26.9 26.9 26.9 26.9 Lipemia (Intralipid)
[00172] Pools of serum from individual donors were enriched with intralipids to concentrations of 0, 100, 250, and 500 mg / dL and quadrupled. Samples were analyzed at each level, and the results are presented in Table 29 and Figure 14. All reported parameters remained within acceptance criteria, except for the highest tested concentration of interferent. Macroscopic lipemic samples are not acceptable for testing. Petition 870260109721, dated 10 / 23 / 2026, page 65 / 141 61 / 64 Table 29. Intralipids TEa: 30% or 1.50 μg / mL Intralipid mg / dL Sample 0 100 250 500 1 37.59 32.92 37.57 39.85 2 2.71 2.65 3.30 3.60 3 31.71 34.62 38.45 38.44 1 33.66 30.24 31.66 37.50 2 3.48 4.22 2.59 3.18 3 29.21 32.21 28.65 35.37 1 30.40 31.08 31.44 34.62 2 3.21 3.54 3.84 2.32 3 28.70 33.07 28.08 38.86 1 32.57 31.55 32.62 33.84 2 3.55 2.87 3.00 2.91 3 30.16 34.68 29.03 37.04 Average 22.25 22.80 22.52 25.63 X +Tea / 3 24.5 24.5 24.5 24.5 X 22.2 22.2 22.2 22.2
[00173] Example 10: Reportable Range. The reportable range for this assay is 1.50 to 50.00 μg / mL.
[00174] Example 11: Reference Range. The reference range for this assay (indicated in the table below) will be adopted by comparison with the currently validated ELISA assay, as a split sample comparison between the candidate LC-EM method and the validated ELISA method, compared over the reference range within TEa / 4. Table 30 BMI Male Female <25 kg / m2 4 to 26 pg / mL 5 to 37 pg / mL 25-30 kg / m2 4 to 20 pg / mL 5 to 28 pg / mL >30 kg / m2 2 to 20 pg / mL 4-22 pg / mL
[00175] The content of articles, patents and patent applications, and Petition 870260109721, dated 10 / 23 / 2026, page 66 / 141 62 / 64 All other documents and information available electronically mentioned or cited herein are incorporated by reference in their entirety, to the same extent that each individual publication was specifically and individually indicated for incorporation by reference. The applicants reserve the right to physically incorporate into this application any and all material and information from such articles, patents, patent applications, or other physical and electronic documents.
[00176] The embodiments described herein may be appropriately practiced in the absence of any element or elements, limitation or limitations, not specifically described herein. Thus, for example, the terms comprising, including, containing, etc., should be read expansively and without limitation. Furthermore, the terms and expressions employed herein have been used as descriptive and not limiting terms, and there is no intention in the use of such terms and expressions to exclude any equivalents of the features shown and described or parts thereof, but it is recognized that various modifications are possible within the scope of the claimed technology. In addition, the phrase consisting essentially of shall be understood as including those elements specifically cited and those additional elements that do not materially affect the basic and innovative features of the claimed technology. The phrase consisting of excludes any unspecified element.
[00177] The present invention is not limited to the particular embodiments described in this application. Many modifications and variations can be made without departing from its spirit and scope, as will become apparent to those skilled in the art. Functionally equivalent methods and compositions within the scope of the invention, in addition to those enumerated herein, will become apparent to those skilled in the art from the preceding descriptions. Such modifications and variations Petition 870260109721, dated 10 / 23 / 2026, page 67 / 141 63 / 64 actions are intended to fall within the scope of the appended claims. The present invention is limited only to the terms of the appended claims, together with the full scope of equivalents to which such claims refer. It should be understood that this invention is not limited to particular methods, reagents, compounds or compositions, which may, of course, vary. It should also be understood that the terminology used herein is intended to describe only particular embodiments and is not intended to be limiting.
[00178] Furthermore, when features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also described in terms of any individual member or subgroup of members of the Markush group.
[00179] As will be understood by one versed in the technique, for all purposes, particularly in terms of providing a written description, all ranges described herein also encompass any and all possible subranges and combinations of subranges. Any listed range can be easily recognized as sufficiently descriptive and allowing the same range to be decomposed into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range described herein can be easily decomposed into a lower third, a middle third, and an upper third, etc. As will also be understood by one versed in the technique, all language such as up to, at least, greater than, less than, and the like, includes the recited number and refers to ranges that can be further decomposed into subranges, as described above. Finally, as will be understood by one versed in the technique, a range includes each individual limb.
[00180] All publications, patent applications, issued patents and other documents mentioned in this specification are here. Petition 870260109721, dated 10 / 23 / 2026, page 68 / 141 64 / 64 incorporated by reference, as if each publication, patent application, issued patent, or other individual document were specifically and individually designated to be incorporated by reference in its entirety. Definitions contained in text incorporated by reference are excluded to the extent that they contradict the definitions of this invention.
[00181] Although certain embodiments have been illustrated and described, it should be understood that alterations and modifications may be made in accordance with the versatility of the technique, without departing from the technology in its broadest aspects, as defined in the following claims. Petition 870260109721, dated 10 / 23 / 2026, page 69 / 141
Claims
1 / 3 CLAIMS 1. Method for determining an amount of adiponectin in a sample by mass spectrometry, characterized in that it comprises: (a) subjecting adiponectin from a sample to an ionization source under suitable conditions to generate one or more adiponectin ions detectable by mass spectrometry; (b) determining the amount of one or more adiponectin ions by mass spectrometry; and (c) determining the amount of adiponectin in the sample from the amount of one or more adiponectin ions determined in step (b).
2. Method according to claim 1, characterized in that the sample comprises a plasma or serum sample.
3. Method according to claim 1 or 2, characterized in that the ionization source is an electrovaporization ionization (ESI) source.
4. A method, according to any one of claims 1 to 3, characterized in that the ionization is in the positive mode.
5. Method, according to any one of claims 1 to 4, characterized in that one or more adiponectin ions comprise an ion having a mass-to-charge ratio (m / z) of 314.18 ± 0.
5.
6. Method, according to any one of claims 1 to 4, characterized in that one or more adiponectin ions comprise an ion having a mass-to-charge ratio (m / z) of 627.36 ± 0.
5.
7. Method, according to any of claims 1 to 4, characterized in that one or more adiponectin ions comprise an ion that has a mass-to-charge ratio (m / z) of 530.30 ± 0.
5.
8. A method, according to any one of claims 1 to 7, characterized in that an internal standard for adiponectin is added to the sample.
9. Method according to claim 8, characterized in that the internal standard is recombinant human adiponectin or adiponectin peptides.
10. Method according to claim 8, characterized in that the method comprises generating one or more internal standard ions that are detectable by mass spectrometry.
11. Method according to claim 10, characterized in that one or more ions of the internal standard comprise an ion having a mass-to-charge ratio (m / z) of 319.19 ± 0.
5.
12. Method according to claim 10, characterized in that one or more ions of the internal standard comprise an ion having a mass-to-charge ratio (m / z) of 637.37 ± 0.
5.
13. Method according to claim 10, characterized in that one or more ions of the internal standard comprise an ion having a mass-to-charge ratio (m / z) of 540.31 ± 0.
5.
14. Method, according to any one of claims 1 to 13, characterized in that it also comprises digestion with trypsin.
15. Method, according to any one of claims 1 to 14, characterized in that it also comprises precipitation with formic acid.
16. Method, according to any one of claims 1 to 15, characterized in that it also comprises the purification of the sample prior to mass spectrometry. Petition 870250088254, dated 09 / 29 / 2025, p. 71 / 106 3 / 3 17. Method according to claim 16, characterized in that the purification comprises subjecting the sample to liquid chromatography.
18. Method according to claim 17, characterized in that the liquid chromatography comprises high-performance liquid chromatography (HPLC).
19. Method, according to any one of claims 1 to 18, characterized in that the mass spectrometry is tandem mass spectrometry.
20. A method, according to any one of claims 1 to 19, characterized in that a low level of adiponectin corresponds to an increased risk of metabolic syndrome.
21. Method, according to any one of claims 1 to 19, characterized in that a low level of adiponectin corresponds to an increased risk of type 2 diabetes. Petition 870250088254, dated 09 / 29 / 2025, pp. 72 / 106
